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ABSTRACT
EFFECTS OF ADRENOCORTICAL STEROIDS
ON
HYPOTHALAMIC PARAVENTRICULAR KNIFE CUT-INDUCED OBESITY
MAY 1988
SUE ANNE ASSIMON, B.A. , COLGATE UNIVERSITY
M.S., UNIVERSITY OF MASSACHUSETTS
Ph . D
.
, UNIVERSITY OF MASSACHUSETTS
Directed by: Professor Richard M. Gold
The present investigation examined whether the
obesity seen subsequent to bilateral parasagittal knife
cuts (KC) alongside the PVN in the rat can be attributed
to diminished adrenal cortical and/or adrenal medullary
activity. Specifically, it examined the effects of the
administration of corticosterone (CORT) , the natural
glucocorticoid of the rat, and dexamethasone (DEX), a
synthetic glucocorticoid documented to enhance
catecholamine (CA) biosynthesis in the adrenal medulla,
upon feeding and body weight.
In Experiments 1 and 2, the effects of the
administration of CORT and of DEX on the obesity produced
by PVN knife cuts were compared. CORT and DEX
differentially influenced regulatory responses. CORT did
not alter the body weight gain or food intake of sham-
operated or PVN KC rats. In contrast, DEX attenuated
weight gain in both PVN KC and brain intact rats, and at
times decreased food intake. In KC rats exposure to DEX
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was associated with greatly elevated blood glucose levels
and sometimes with glycosuria.
In Experiment 3, the nature of the suppressive
effects of DEX was explored further. The role of the
adrenal medulla and of pituitary ACTH were examined. The
adrenal medulla did not prove to be the major site at
which DEX acts to suppress body weight and food intake.
However, the participation of adrenal medullary CAs in
DEX-induced effects on glucose homeostasis in KC adrenal
intact rats was indicated. DEX's inhibition of pituitary
ACTH was not revealed as contributing to the altered
ingestive responses produced by DEX. Thus, the involvement
of other sites in DEX's suppressive effects was suggested.
Because supplements of CORT or ACTH did not block the
hypothalamic obesity syndrome, deficits in the
availability of circulating CORT or in pituitary ACTH did
not emerge as causing the overeating and obesity that
follow PVN KCs. Definitive conclusions about the
relationship between the obesity induced by PVN KCs and
altered adrenomedullary CA activity could not be drawn
from this work. Direct measures of adrenal medullary
functions are needed.
Finally, this work revealed that the glucocorticoids
CORT and DEX markedly differ in their effects on body
weight, food intake, growth, and blood glucose levels.
Possible explanations for the dissimilar effects of these
glucocorticoids were addressed.
ix
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CHAPTERI
INTRODUCTION
The medial hypothalamus has long been recognized as
playing an integral role in the regulation of feeding and
body weight. Within this area, the paraventricular nucleus
(PVN) is now distinguished as focal in the control of
ingestive and metabolic processes. Both surgical and
pharmacological manipulations which serve to inactivate
the PVN promote eating and weight gain. For instance,
medial parasagittal hypothalamic lesions (36, 45, 89) and
knife cuts (43, 44, 48, 49, 76), which either disrupt this
nucleus or its connections, produce chronic increases in
food intake and body weight. The PVN thus appears to
inhibit feeding. Injections of nor epinephrine (NE) or nor
adrenergic agonists into the medial hypothalamus (92, 93,
113, 154) or even the cerebral ventricles (131) of the rat
reliably stimulate a feeding bout. The PVN is the most
effective and most sensitive injection site (87, 88, 90,
92). This point is further substantiated by the finding
that discrete PVN lesions prevent the feeding behavior
typically elicited by central NE injections (96).
Recently, attempts have been made to integrate the
acute feeding response seen after injections of NE into
the PVN and the long-term food intake and body weight
changes seen after surgical interruption of the PVN. When
central infusions of NE are made 4 times a day (99), or
1
chronically in a continuous or pulsatile fashion (102),
rats demonstrate increases in total daily food intake and
body weight gain across the series of days that NE
exposure is continued.
Along with being recognized as a site that plays an
integral role in ingestive processes, the PVN is
responsible for the modulation and integration of
neuroendocrine and of specific visceral secretory
functions (158, 162, 185, 188).
General Experimental Focus
The major neuronal projection systems associated
with the PVN govern the expression of the functions of
this nucleus. One projection system mediates the activity
of the pituitary-adrenal system via paraventricular
projections to the median eminence. Another system is
comprised of the neural interconnection between the PVN
and catecholaminergic and autonomic sites in the
myelencephalon and spinal cord and mediates gustatory,
visceral, and autonomic responses. Each of these
paraventricular projection systems influences the adrenal
glands. The former influences the activity of the adrenal
cortex via adrenocorticotropic hormone (ACTH) release from
the anterior pituitary, while the latter influences the
adrenal medulla via autonomic sites in the spinal cord.
The present investigation examined the role of the
adrenal cortex and adrenal medulla and their secretions in
2
the obesity that results after disconnection of the PVN.
It specifically examined the effects upon feeding of the
administration of corticosterone, the natural adrenal
glucocorticoid of the rat, and dexamethasone, a synthetic
glucocorticoid that also significantly alters catechol-
amine (CA) biosynthesis in the adrenal medulla.
Hyperphagia and obesity was induced by bilateral
parasaggittal retracting wire knife cuts alongside the
PVN. This allowed reference to and comparison with the
existing literature that deals with this type of
experimentally-induced obesity.
The remainder of this chapter is a survey of the
literature associated with the neuroanatomical and
functional characteristics of the PVN and of related
findings associated with the medial hypothalamic area.
The discussion focusses on the relationship between each
projection systems of the PVN and ingestion.
Adenohypophysial Connections of the PVN
Neuroanatomy
Many studies have implicated the medial
hypothalamus in the control of the pituitary-adrenal
system. Recent work characterizes the PVN as the nucleus
within this area primarily responsible for modulating the
activity of this neuroendocrine system. The PVN contains
the cell bodies of the neurons that possess the 41-amino-
acid peptide Corticotropin Releasing Factor (CRF) (164,
3
168, 190). Several immunocytochemical studies locate a
large population of immunoreactive CRF cell bodies in the
parvocellular division of the PVN (11, 119, 120, 139,
165). CRF immunopositive efferent fibers project from the
PVN to the external lamina of the median eminence (11,
120, 139, 168) where they terminate on the primary portal
capillaries ( 40 , 119 )
.
The hypophysiotropic role of CRF is supported by the
experimental conditions under which enhanced
immunocytochemical staining for CRF is seen. In normal
intact rats minimal immunopositive staining of CRF
neuronal perikarya is found without pretreatment with
colchicine (139, 165, 168). Colchicine, which blocks
axonal transport, increases CRF-immunostaining in the PVN
(11, 119, 165, 168, 190). This enhancement is accompanied
by decreased CRF staining in the median eminence (11,
119). This indicates that CRF is synthesized in the PVN
and transported by axoplasmic flow to terminals in the ME.
The responsiveness of CRF to feedback inhibition is
demonstrated in adrenalectomized and in hypophysectomized
rats. The loss of negative feedback from the pituitary-
adrenal system in these rats is accompanied by an enhanced
immunostaining of CRF cells (120, 139, 165, 168, 190).
Direct evidence confirming the role of CRF in the
secretion of ACTH has been obtained using live animals.
The increase in ACTH levels induced by exogenously-applied
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CRF, by ether stress, or by the loss of negative feedback
associated with adrenalectomy is substantially attenuated
by antibody antiserum to CRF (151, 152). It has also been
shown that a circadian rhythmicity in CRF-like
immunoreactivity in the hypothalamus leads and parallels
the circadian rhythmicities of ACTH and corticosterone
(125) .
Feeding
Some evidence suggests that the mediation of
consummatory behaviors by the PVN may relate to this
site's influence on the function of the pituitary-adrenal
system. Hypothalamic hyperphagia and obesity are altered
by removal of the pituitary or the adrenals. The obesity
produced by lesions of the VMH (which destroy fibers of
passage from the PVN) is prevented by adrenalectomy (26,
70). This effect appears to be due to the loss of adrenal
steroids, because corticosterone replacement reinstates
the hyperphagia and weight gain characteristic of VMH-
lesioned animals (26). The feeding response induced by
the central infusion of NE also relies on the presence of
pituitary and adrenal glands. Hypophysectomy abolished the
feeding, but not drinking, behavior exhibited after
centrally-applied NE (88, 91, 98, 154). The consummatory
response elicited by PVN injections of NE or clonidine is
attenuated by prior adrenalectomy (10, 91, 98, 153). In
each case the behavioral deficits are reversed by
corticosterone replacement therapy. In addition, the
hormone-reinstated food intake response is positively
correlated with the level of circulating corticosterone
made available ( 91 , 98 , 153 )
.
Circadian Rhythms
On a 12:12 lightrdark cycle the diurnal variations
of adrenocortical secretions, food intake, and activity in
the rat coincide (32, 78, 79). Peak ACTH and
corticosterone levels occur just prior to the onset of
dark (32, 78, 79, 205), the phase in which ad libitum-fed
rats typically consume most of their food (8, 68, 150,
175) and are the most active (35, 78). A range of evidence
suggests that the periodicities of these rhythms are
intricately interrelated. For example, under restricted
feeding regimens rats shift their diurnal corticoid
rhythms such that the peak in corticosterone levels occurs
just prior to the times of meal presentation (32, 78, 90,
124). Under conditions of prolonged food deprivation,
circadian rhythms for activity and corticosterone are
not present (32, 72). Under conditions of constant
light or constant dark, food intake, activity, and
corticosterone rhythms are not synchonized and are seen to
free-run in accordance with the endogenous rhythm of each
(32, 77). However, under constant light or dark, food can
serve as a zeitgeber for corticosterone and activity
rhythms because both of these rhythms can be entrained to
a discrete food presentation schedule (32, 128).
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The medial hypothalamus has been implicated as an
anatomic substrate of these interrelated circadian
rhythmicities. Disruption of the PVN or the VMH abolishes
or attenuates the 12:12 diurnal rhythms normally
associated with feeding (8, 32, 64, 68, 174, 175),
activity (32, 37, 41, 64, 66), and corticosterone (9, 32,
80, 174). The obesity produced by this manipulation has
been attributed at least in part to the elevated daytime
food intake along with the accompanying loss of nighttime
activity. In addition, the periodicity documented for the
feeding response mediated by adrenergic receptors in the
PVN appears to be dependent on circulating corticosterone,
because adrenalectomy suppresses the food intake induced
by NE or clonidine more during the nighttime, when
corticosterone levels are normally high, than the daytime,
when corticosterone levels are normally low (10).
Disruption of Hypothalamo-Adenohypophysial Connections
The PVN emerges as the key neural substrate for the
regulation of both the hypothalamo-pituitary-adrenal axis
and consummatory behavior. It has been well-established
that disruption of the PVN results in profound changes in
food intake and body weight gain (eg. 48, 97, 174). In
recent years, a range of work has also revealed that
disruption of the PVN produces changes in the functioning
of the hypophysial-pituitary-adrenal system (eg. 107, 108,
109). Since the focus of the present investigation is to
examine how the changes in feeding behavior seen after
7
parasagittal knife cuts made alongside the PVN relate to
the function of the adrenal gland, it is useful to examine
the nature of adenohypophysial-adrenal functions
subsequent to interruption of the PVN.
First, disruption of the PVN in rats reduces
adrenal weight (107, 109), attenuates the amplitude of
circadian ACTH and cortlcosterone rhythms (67, 107, 174),
and lower circulating cortlcosterone levels (67, 109,
174). However, some laboratories do not find changes in
basal cortlcosterone levels (107, 108).
Stress response tests, a procedure commonly
utilized to assess the functioning of the hypothalamus-
pituitary-adrenal axis, have been performed on rats that
have experienced either electrolytic lesions of the PVN or
isolation of the PVN by a rotating wire knife. Animals
exposed to either of these procedures show a diminished
capacity to respond to stress. Disruption of the PVN
results in a transient reduction in the increments in
plasma cortlcosterone levels that typically accompanies
exposure to a stress (see Table 1). This diminished
cortlcosterone stress response is present 1 week (108,
109) and 3 weeks (67) after receiving PVN surgery but not
after 4 weeks (107, 108, 109).
Both pituitary ACTH content and ACTH release are also
influenced by deletion of the PVN (see Table 1) . Bruhn
et.al. (27) found that at approximately one week after
8
TABLE 1
A SUMMARY OF THE STATUS OF THE PITUITARY-ADRENAL SYSTEM OF
RATS AFTER SURGICAL DISRUPTION OF THE PVN
Short-term Long-term
CORT: stress response
plasma levels
attenuated* normal
ACTH: pituitary content elevated
stress-free
plasma levels
normal normal
stress response
plasma levels
diminished normal
IV CRF-stimulated
plasma levels
greatly-
elevated
CRF-stimulated
release in vitro
elevated
Short-term = represents data collected 1-4 weeks after surgery.
Long-term = represents data collected 5 or more weeks after surgery
* ~ assessments made with respect to values obtained from rats that
received only sham hypothalamic surgery
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surgery PVN-lesioned rats have a 50% elevation in the
pituitary concentration of ACTH-like immunoreactivity
.
This did not influence ACTH release under stress-free
conditions, because the basal levels of plasma ACTH ofPVN-
operated rats did not differ from control rats at 6 days
(27), 3 weeks (67), and 6 weeks (107, 108) after surgery.
In contrast, when rats are presented an ether stress (27),
or a high level lapatomy-intestine traction stress (108) 6
days after PVN surgery, the stress-induced release of
plasma ACTH is diminished 45 to 85% of controls. However,
when PVN-lesioned rats are given IV ovine CRF at this
time, they exhibit a dramatic 125-328% enhancement of
plasma ACTH levels as compared to sham-operated controls
(27). These results suggest an enhanced sensitivity to CRF
after disruption of the PVN. Indeed, by 6 weeks post-
surgery rats with PVN knife cuts exhibit the same
increase in plasma ACTH levels in response to stress as do
control rats (108). Similarly, 6 weeks after transection
of the PVN, an elevated release of ACTH is found in
response to CRF in an in vitro incubated anterior
pituitary preparation (108). In sum, although the
response of rats with PVN lesions or rotating wire knife
cuts to acute stresses, as measured by plasma
corticosterone and ACTH levels, may recover over time, the
underlying functional status of the neuroendocrine axis of
these animals is not the same as intact rats.
This point is also suggested by the results of work
10
from other procedures utilized to assess the
responsiveness of the hypothalamo-pituitary-adrenal
system. For example, transection of the PVN inhibits the
compensatory adrenal hypertrophy that typically follows
unilateral adrenalectomy (110).
The loss of negative feedback by bilateral
adrenalectomy is characteristically accompanied by
increases in ACTH levels under both in vivo and in vitro
conditions ( 107 , 108 , 109 , 202 ) . However, rats that
undergo adrenalectomy 8 days after rotating wire knife
cuts of the PVN do not exhibit enhanced plasma ACTH levels
(109). Even when the adrenals are removed 6 weeks after
the PVN cuts, there is no compensatory increase in plasma
ACTH, or in basal or CRF-stimulated in vitro ACTH release
from anterior pituitary quarters (108) (see Table 2).
A dichotomy appears to exist between pituitary ACTH
responses to stress and to adrenalectomy after destruction
of the PVN. As Makara (107, 108) suggests, it appears
that long-term PVN-lesioned or -knife-cut rats can
compensate and respond to a brief challenge such as acute
stress, but not to a sustained stimulus to ACTH release
such as adrenalectomy. It has not, however, been
determined whether PVN-operated rats could maintain the
stress-induced release of ACTH or corticosterone if the
stress was continued over long periods of time. Because
the consummatory responses of animals with PVN lesions or
11
TABLE 2
A SUMMARY OF PITUITARY RESPONSES SEEN SUBSEQUENT TOBILATERAL ADRENALECTOMY IN PVN KNIFE-CUT AND SHAM-OPERATED RATS
Short-term Long-term
ACTH: plasma levels
Sham KG Sham KG
inc* no inc inc no inc
basal release
in vitro inc no inc
CRF-stimulated
release in vitro inc no inc
Short-term
- represents responses seen when adrenalectomy is performed
approximately 1 week after sham or PVN knife cut (KG)
surgery.
Long-term = represents responses seen when adrenalectomy is performed
6 weeks after sham or PVN KG surgery.
* inc = increase
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knife cuts are typically studied over extended periods of
time, which includes these animals encountering various
and repeated stressors in their daily lives, this is a
relevant issue. The findings suggests that the
demonstration of normal basal and stressed levels of
corticosterone in short-term tests may not in itself
represent an uncompromised hypothalamus-pituitary-adrenal
system. Overall, it appears that the interruption of CRF-
ACTH connections can disturb the capacity and response of
the pituitary-adrenocortical system.
Extrahypophysial Interconnections of the PVN
Neuroanatomy
In addition to its parvocellular projections to the
median eminence which serves the anterior pituitary, the
PVN possesses two other major types of neuroanatomical
connections. One is the classical magnocelluar
neurohypophysial projection, and the other class consists
of neural parvocellular connections to other sites within
the brain and spinal cord (158, 186, 187, 188).
Most of the projections of the magnocellular
division of the PVN are to the posterior pituitary (186,
187, 188, 209). The magnocellular neurosecretory system is
principally involved in the homeostasis of water balance.
It is not considered in itself to play a major, or direct,
role in feeding.
The parvocellular division of the PVN has extensive
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bidirectional connections with the brainstem and the
spinal cord (see Figure 1). These include a number of
interconnected noradrenergic brainstem cell groups (158,
162, 186, 187, 188). These noradrenergic pathways relay
visceral sensory information to the PVN* The PVN also
contains parvocellular neurons that project to the locus
coeruleus (LC) and to preganglionic cell groups of the
autonomic nervous system (ANS) in the dorsal vagal complex
(DVC) and the interomediolateral column (IMLC) of the
spinal cord (105, 162, 163, 179, 184, 186, 188). These
projections mediate autonomic responses associated with
both the parasympathetic and the sympathetic divisions of
the ANS (158, 162, 187).
Feeding
The localization of a 41-amino acid CRF peptide,
considered the primary corticoliberin, to cells of the PVN
has served to focus the study of the feeding responses
mediated by the PVN toward an examination of the
pituitary-adrenal axis. However, the neural projections
between the PVN and brainstem also seem to contribute to
the regulation of ingestion.
The overeating and obesity seen subsequent to the
disruption of PVN neurons appear to be the greatest when a
substantial interruption of the hindbrain projection
fibers to and/or from the PVN is involved. Several
reports have revealed that the PVN lesions that are the
most effective in producing hyperphagia and body weight
Figure 1. Diagraminatic representation of the major
afferent and efferent neural pathways associated with the
PVN of the hypothalamus (PVH) of the rat from Sawchenko and
Swanson (162)
.
A. A summary of the organization of noradrenergic (NAc)
inputs to the PVN, and the interconnections among the cell
groups that give rise to these projections,
B. A summary of the major outputs of the PVN.
Principal Abbreviations: ME, median eminence; PP,
posterior pituitary; LC, locus coerulus; DVC, dorsal vagal
complex; IML, intermediolateral cell column; Al , NAc cells in
Al cell group; IX and X, glossopharyngeal and vagal cranial
nerves
,
respectively
.
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gain are lesions that damage the caudal aspect of the PVN
(2, 97, 171 as noted in 2). Furthermore, coronal
hypothalamic knife cuts increase food intake and weight
gain when cuts are made caudal, but not rostral, to the
PVN (48, 172). This localization coincides with the
routes of direct neural connections between the PVN and
autonomic nuclei of the lower brainstem as determined by
anterograde and retrograde tracing techniques. The cells
of origin of descending projections in particular, but
also sites of termination of ascending projections to some
degree, are found to concentrate in the caudal aspect of
the PVN (163, 188)
.
The hyperphagia and obesity produced by hypothalamic
PVN knife cuts can be prevented or even reversed by
complete subdiaphragmatic vagotomy (159). The branch of
the abdominal vagus most responsible for this attenuation
is the coeliac branch (160) which innervates the
pancreas and part of the small intestine. These findings
indicate the involvement of the parasympathetic division
of the ANS and thus, the participation of autonomic nuclei
in this syndrome.
The evidence accumulated to date points to the
disruption of efferent descending projections of the PVN
rather than afferents to this nucleus as key in the
hypothalamic obesity syndrome. Damage to noradrenergic
afferents results in hypophagia and reduced body weight
(94, 135). Similarly, the destruction of noradrenergic
innervation to the PVN with the neurotoxin 6-hydroxy-
dopamine causes decrements in food intake (5, 149). In
contrast, increases in food consumption and body weight
follow the destruction of PVN efferents as they course
through the midbrain or thalamic periventricular gray
regions en route to the DVC (204). In addition, the role
of descending caudal outputs of the PVN is established for
the eating elicited by central injection of noradrenergic
agonists (111, 161, 204).
In the present investigation paraventricular fibers
were cut bilaterally alongside the PVN. These parasagittal
knife cuts sever medio-laterally oriented axons leaving or
entering the PVN (2, 3, 48). After travelling to the
lateral hypothalamus, PVN efferent projections turn
caudally and/or ventrally. Work using asymmetrical knife
cut and/or lesion techniques (47, 48, 172, 173) or
staining procedures (105, 173, 184) suggest that the
longitudinal fiber pathway that is relevant to the
expression of paraventricular hypothalamic obesity courses
through the basolateral hypothalamus into the midbrain,
taking a path over the substantia nigra in the pontine
tegmentum as it travels to sites in the caudal hindbrain.
Over the years, investigators have put forth the
notion that the obesity syndrome associated with damage to
the medial hypothalamus is a reflection of an alteration
in the functioning of the ANS (15, 16, 56, 103, 144, 158).
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They suggest that this damage results in an increase in
parasympathetic activity together with a decrease in
sympathetic activity, which encourages increased food
intake and weight gain. A range of experimental tests of
this hypothesis, particularly with respect to disruption
of the VMH, have been performed (15, 31, 146, 159, 160,
170). But the findings of these studies have rendered
discrepant conclusions. In light of the evidence that PVN
efferents innervate preganglionic cell groups and relay
nuclei of the ANS, it seems more plausible that the PVN is
the medial hypothalamic site that influences the activity
of the ANS and plays a role in the obesity that develops
after PVN knife cuts.
Extrahypophysial CRF System
Several authors have proposed the existence of
another major CRF system which is for the most part
anatomically and functionally distinct from the
paraventriculo-infundicular CRF projection system (116,
118, 141, 167). The primary functions of this system are
posited to involve the central control of both divisions
of the ANS and the mediation of a variety of autonomic
responses
.
The physiological state associated with this CRF
system is the converse of the one thought to be
responsible for the hypothalamic obesity syndrome. As
determined by the measurement of a number of physiological
responses, the central administration of CRF decreases
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parasympathetic outflow and increases sympathetic outflow.
CRF acts within the CNS, independently of its effects
on ACTH (21, 24), to induce changes in sympathetic nervous
system (SNS) activity. The administration of CRF into the
intracerebral ventricles of rats produces a rapid and
prolonged elevation of plasma epinephrine (E) and NE
levels (23, 24). The ganglionic blocker, chlorisondamine,
antagonizes these CRF-induced increases in peripheral CA
concentrations (24), and centrally-applied CRF receptor
antagonists suppress stress-induced elevations of plasma E
(21). Finally, increases in oxygen consumption also
accompany the central, but not peripheral, infusion of CRF
(23) .
CRF also influences the autonomic control of gastric
acid secretion (GAS). Microinfusions of CRF into the PVN
(59, 19 3) or the cisterna magna (192) of the rat produces
a dose-dependent and long-lasting inhibition of basal and
pentagastrin-stimulated GAS. The inhibition of GAS
following intracisternal (ICT) injections persists after
hypophysectomy (192), which indicates that it is
independent of the hypophysiotropic actions of CRF.
Support for the contribution of the parasympathetic
nervous system (PNS) in this response exists. Vagal
activation is established as critical in the GAS response
elicited by pylorus ligation, ICT thyrotropin-releasing
hormone infusions, and IV pentagastrin injections. Central
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CRF suppresses the secretion of gastric acid typically
stimulated under each of these experimental conditions
(192, 193). Moreover, prior vagotomy reduces the
inhibitory action of CRF on GAS (192, 193). The ability
of CRF to act within the brain to suppress GAS also
appears to encompass the activity of the sympathetic
division, because prior adrenalectomy, administration of
ganglionic or alpha-adrenergic blockers, or transection of
the spinal cord at the cervical C5 level, attenuates the
suppression of GAS by ICT CRF (193). A complete blockade
of the inhibition of GAS by CRF is seen in rats after
vagotomy plus adrenalectomy (192). Finally, support for
the physiological basis of this response is provided by
the finding that the stress-induced release of endogenous
CRF decreases GAS (115, 169, 193).
Changes in peripheral metabolism are also produced by
the central administration of CRF. Intracerebrally-
applied CRF elevates plasma glucagon ( 24 ) , and plasma
glucose in a dose-related manner (21, 23, 24, 25). The
hyperglycemia stimulated by CRF is not related to this
peptide's tropic actions on the pituitary gland, because
hypophysectomy did not prevent it (24). Evidence
suggests this elevation in glucose is at least partially
mediated by the enhanced levels of peripheral CAs that
also accompany the infusion of CRF (21, 24).
In addition to influencing the vegetative state of an
animal, the central application of CRF can modify
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behavior. It increases locomotor activity (23, 73, 183),
enhances the behavioral effects of novelty (17, 18, 73),
and increases grooming (17, 18, 73, 129, 183). These
behavioral enhancements are exhibited in hypophysectomized
rats (73, 129), but not when CRF is injected peripherally,
nor when an inactive CRF analog is administered (183).
CRF also influences food intake. CRF applied ICV decreases
food intake under a number of test conditions (17, 18, 54,
73, 101, 129). Deprivation- induced feeding is suppressed
when CRF is injected into the PVN but not other brain
nuclei (75). The suppression of nocturnal feeding seen
after CRF injections exists after hypophysectomy (129) but
not after adrenalectomy (54), and is not reinstated by
corticosterone replacement (54). As would follow, ICV
infusions of CRF did not significantly reduce food intake,
except at a high dose, in adrenal demedullated rats (54).
Taken together, these results indicate that CRF's
suppression of eating is not dependent on the pituitary-
adrenocortical axis. The influence of centrally-applied
CRF on ingestion appears to result from the changes it
produces in the ANS particularly in the SNS.
The responses elicited upon activation of autonomic
circuitry within the CNS by CRF generally oppose the
responses produced by interruption of the PVN (see Table
3). Converse to the responses elicited by central
injections of CRF, knife cuts alongside the PVN increases
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TABLE 3
A COMPARISON OF THE RESPONSES ELICITED BY RATS AFTER RECEIVING
PARASAGITTAL KNIFE CUTS ALONGSIDE THE PVN OR CENTRAL INJECTIONS OF CRF
TYPE OF RESPONSE PVN KNIFE CUTS CENTRAL CRF
Food intake
T I
Locomotor Behavior
i T
Grooming Behavior
i r
Gastric Acid Secretion T i
Plasma Glucose Levels
I*
Plasma Glucagon Levels i r
Plasma E Levels I r
Plasma NE Levels varies
Energy Expenditure
sir t
= represents an increase represents a decrease
* = represents glucose levels just following KC surgery and prior
to ad libitum access to food.
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food intake (eg. 48), decreases in activity (37),
decreases grooming behavior (personal observation), and
increases GAS (159). The latter indicates an alteration in
the status of PNS activity. Contrary metabolic and
sympathetic responses are also seen. Within a short time
after PVN surgery, plasma glucose falls (6, 50, 65),
plasma glucagon falls, and plasma E is greatly diminished,
as is the E/NE ratio (50). Rats with PVN knife cuts also
have a diminished capacity for thermogenesis (31, 61).
Since the constellation of responses influenced by
the activation of autonomic circuitry and by knife cuts
along the PVN parallel each other, similar physiological
systems may underlie both set of responses (see Figure 2).
The results from a range of neuroanatomical and
electrophysiological work lend additional support to this
idea. First, some CRF-immunoreactive (ir) labeled cells in
the parvocellular division of the PVN give rise to
extrahypophysial descending autonomic projections (164).
Double-labelling techniques reveal a substantial number of
long direct projections to autonomic sites in the
brainstem and the sympathetic IMLC of the spinal cord
originate from PVN cells and stain for oxytocin,
vasopressin, and neurophysin (163, 179, 184, 188, 209).
These neuropeptides have not emerged as being significant
in the mediation of autonomic responses (20), but CRF has
been shown to coexist with all three of these peptides in
the PVN (71, 116, 164, 165, 166). Next, CRF-ir has been
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Figure 2. Diagrammatic representation
of the
parave^itricular hypothalamic-pituitary-adrenal
axxs and the
paraventricular extrahypophysial projections that
control
Eoth the parasympathetic and the sympathetic
divisions of the
autonomic nervous system. ^ f^nmr*
Principal Abbreviations: CRF. corticotropin
release actor
ACTH adrenocorticotropic hormone; E,
epinephrine; IMLC, mtero
mediolateral column; CAs, catecholamines.
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demonstrated in cells of the LC, and cells and fibers of
the nucleus of the solitary tract (NST), dorsal motor
nucleus of the vagus (DMNV), the central nucleus of the
amygdala, and the laminae of the thoracic and lumbar
levels and IMLC of the spinal cord (116, 136, 137, 141,
190). In addition, CRF-ir has been located in other
neuroanatomical sites known to be relevant to the
processing of visceral and gustatory information such as
the sensory glossopharyngeal, vagal, and hypoglossal
nuclei, the nucleus ambiguus, the parabachial nucleus, the
trigeminal nucleus, and the medullary regions that contain
CA cell groups (116, 136, 137, 167).
Furthermore, CRF alters electrophysiological activity
in the brainstem. CRF given by ICV injections or by local
microapplication activates neural firing in the LC (201).
In turn, electrostimulation of the LC in the cat activates
the adrenal medulla releasing CAs (42). In addition, CRF
and oxytocin have been identified within the adrenal
medulla in the rat (62, 141).
These findings strengthen the assertion that the
obesity seen after the disruption of the PVN can be
attributed, at least in part, to the severing of PVN
caudal efferent projections.
PVN Projections and Their Relationship to the Adrenal Gland
Two major projections of the PVN share a common
target the adrenal gland.
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Caudal projections from the PVN innervate autonomic
cell groups in the IMLC of the spinal cord which are the
source of preganglionic sympathetic fibers to the adrenal
medulla. Disruption of the PVN or its hindbrain
projections are posited to diminish the activity of these
splanchnic nerves.
CRF-positive paraventriculo-infundibular neural
projections are primary in the control of the pituitary-
adrenal axis. In turn, interruption of the PVN or its
hypophysial projections reduces the responsiveness of the
pituitary-adrenocortical system. Studies that examine the
integrity of the hypothalamo-dpituitary system typically
focus on the status of the adrenal cortex: circulating
corticosterone levels, and the influence of circulating
corticosterone levels on peripheral and central sites.
Examination of the relationship between the hypothalamic-
pituitary-adrenal system and ingestion also focus on these
aspects of adenocortical function. Indeed, this work has
revealed that circulating corticosterone levels play a
significant role in the expression of consummatory
responses (26, 32, 70, 97) and the mediation of a range of
metabolic processes (63, 122, 140).
However, these lines of investigation tend to neglect
another significant component of the function of the
adrenal cortex. In addition to secreting corticosterone
into the blood, the adrenal cortex influences the
secretions of the adrenal medulla. Any manipulation which
27
compromises the responsiveness of the adrenal cortex can
Indirectly Influence the status of the adrenal medulla (4,
30, 39, 83, 207, 208).
The adrenal gland consists of an outer cortical
region where glucocorticoids are synthesized, an inner
medullary region that contain chromaffin cells where CAs
are synthesized, and a portal vascular system that allows
undiluted adrenocortical venous blood to perfuse the
medulla. The regulation of CA biosynthesis in the adrenal
medulla is affected both by the activity of the splanchnic
nerves and by the concentration of glucocorticoids in the
medulla. The neural and humoral factors jointly modulate
the enzymes responsible for the synthesis of medullary CAs
and influence the proportions of E and NE produced.
The effects of the neural and humoral inputs on CA
synthesis in the adrenal medulla have been illustrated in
a range of work. Experimentally-induced increases in the
enzymes involved in the biosynthesis of CA, tyrosine
hydroxylase (TH) , dopamine B-hydroxylase (DA-B-OH), and
phenylethanolamine-N-methyl transferase (PNMT) , can be
abolished by transecting the splanchnic nerves to the
adrenal (39, 83, 134, 197, 198). Hypophysectomy , which
eliminates corticotropic stimulation of the adrenal
cortex, also reduces the activity of CA biosynthetic
enzymes in the adrenal medulla (4, 30, 39, 83, 197, 207,
208). This effect is reversed by exogenous ACTH (4, 30,
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39, 83, 207, 208) or the synthetic glucocorticoid DEX (4,
39, 83, 197, 207, 208)
.
Adrenal Secretions
The adrenal gland is responsible for the production
and release of a multitude of humoral substances. As
mentioned the catecolamines NE and E are synthesized and
released by the adrenal medulla. Also a range of steroid
hormones are manufactured from a common precursor,
cholesterol, within the cells of the adrenal cortex and
are secreted into the blood supply. The glucocorticoids,
which influence intermediary metabolism, are one major
class of adrenocortical steroid hormone. This group of
hormones consists of Cortisol (or hydrocortisone),
cortisone, and corticosterone. Another major class of
adrenocortical steroids are the mineralocorticoids . They
contribute to the regulation of fluid-electrolyte balance.
The principal mineralocorticoid that circulates is
aldosterone, but small amounts of deoxycorticosterone is
also formed and released. Lastly a group of steroids
having androgenic or estrogenic activity is also
manufactured by the adrenal cortex. Testosterone is
produced in small amounts. Moderately active male sex
hormones called adrenal androgens are also liberated.
These include dehydroepiandrosterone, androstenedione, and
11-B-hydroxyandrostenedione. The female sex hormones of
progesterone and estrogen are secreted but only in minute
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quantities
.
The predominant naturally occurring glucocorticoid
in the rat is corticosterone (CORT). The molecular
structure of this corticosteroid follows:
It is derived from the basic steroid molecule which
consists of four carbon rings fused together with three
six-membered rings and a fourth five-membered ring.
In the present investigation the effects of CORT
are compared to those of a synthetic analogue of this
steroid, dexamethasone (DEX)- DEX is a modification of the
synthetic adrenocortical compound prednisolone. The
molecular structure of each of these synthetic
glucocorticoids is represented as follows:
0
Corticosterone
CH2OH CH2OH
Prednisolone ( 9 oc Pluoro-1 6 ^ methyl-prednisolone
)
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The primary difference between these synthetic
steroid analogues and the natural adrenocorticoid CORT is
a 1,2-double bond in the A ring of the basic steroid 4
ring nucleus, and the -OH in the C-17 position.
Although glucocorticoids are primarily considered
for their glucose-promoting effects, they do often also
possess some salt-retaining mineralocorticoid potency.
This is the case for corticosterone. However the
structural modifications in the composition of DEX noted
above contributes to the enhancement of the glucocorticoid
potency of DEX but essentially eliminates its
mineralocorticoid effects.
For the most part CORT and DEX are used
interchangeably as glucocorticoid agents. However, over
time some difference in their actions and in the effects
they produce have been evidenced.
In addition to its traditional classification as a
glucocorticoid agent, DEX is established as an activator
of CA biosynthetic enzymes, particularly PNMT, in the
adrenal medulla (143, 207, 208). DEX appears to have a
greater capacity to influence the adrenal medulla in this
manner than exogenously-applied CORT does (207).
The negative feedback action of CORT and DEX also
differs to some extent. CORT has greater binding affinity
to hypothalamic and limbic sites than to the anterior
pituitary (34, 147), while the converse holds for DEX (33,
34, 148). CORT also exhibits a greater capacity to
inhibit
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CRF at the hypothalamic level than ACTH release at the
pituitary level (156, 157). Again the reverse is true for
DEX (148, 156, 157)
.
A survey of the findings available to date reveals
that the body weight of rats is affected differently by
these corticosteroids. Several reports indicate that the
administration of DEX results in decreases in body weight
(7, 104, 140, 178). Another prednisolone-based
glucocorticoid, methylprednisolone, is also found to
diminish the body weight gains of normal and VMH-lesioned
rats (52, 53). However, corticosterone given to normal
rats does not affect body weight (140, 178) and in some
instances appears to potentiate body weight gain (57,
106)
.
The significance of the disparities that do exist
between CORT and DEX and the role they play in the
responses seen herewithin are addressed throughout this
investigation.
Overview
The present investigation assessed whether the
obesity seen subsequent to bilateral parasaggital knife
cuts alongside the PVN can be attributed to alterations in
adrenal cortical and/or adrenal medullary activity.
Review and Rational
The PVN and its projections are integral in
controlling the pitutary-adrenocortical system and in
modulating the activity of the ANS.
CRF-positive paraventriculo-infundibular projections
link the PVN to two aspects of the function of the adrenal
cortex. By its control of adrenocorticotropic stimulation
of the adrenal cortex, the PVN regulates the level of
circulating CORT, and also indirectly mediates the
intraadrenal supply of CORT flowing to the adrenal
medulla. The latter adrenocortical effects, in turn, is
significant to the activity of the adrenal medulla as it
is one factor that regulates CA synthesis in the adrenal
medulla. Support for this is derived from the decline in
adrenomedullary TH, DA-B-OH, and PNMT activity and E
content produced by hypophysectomy and its reversal by
ACTH (4, 39, 83, 85, 207, 208).
Paraventricular projections to autonomic sites in the
caudal aspect of the CNS also impose on the function of
the adrenal gland. Via these efferents, the PVN modulates
the SNS which includes the sympathetics innervating the
adrenal medulla. Neural stimulation of the adrenal medulla
via splanchnic nerve fibers is the other major factor
contolling adrenomedullary CA production. Activation of
adrenal medullary CA biosynthesis is prevented by adrenal
denervation and by cutting sympathetic nerves to the
superior cervical ganglia (4, 39, 83, 197, 198).
Thus, the PVN emerges as a unique neuroanatomical
site which influences the activity of the adrenal cortex
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and medulla. These influences include a functional
relationship with the two factors that modulate
adrenomedullary CA synthesis.
It follows that knife cuts alongside the PVN of the
hypothalamus should affect the function of both parts of
the adrenal. As documented in previous sections,
disconnection of the PVN reduces the responsiveness of the
pituitary-adrenocortical system and diminishes sympathetic
activation of the adrenal medulla. Hence, the manufacture
of CAS in the adrenal medulla would be altered by
interruption of the PVN and/or its projections.
The studies herewithin explored the possibility that
KC-induced alterations in adrenal secretions contribute to
the obesity that results after transection of the PVN.
CORT and DEX were employed to test this possibility. If
the obesity produced by PVN KCs relates to insufficiencies
in the levels of circulating CORT available, CORT should
ameliorate the obesity. If, however, PVN KC-induced
obesity is instead linked to deficits in the production
and balance of available adrenomedullary NE and E, then
only DEX treatments should attenuate the propensity for
weight gain in KC rats. The synthetic steroid DEX is
capable of reinstating the medullary CA biosynthetic
enzyme activity in rats with disrupted adrenocortical
and
neural connections to the adrenal medulla as it can
activate these enzymes in hypophysectomized and
adrenal
denervated rats (eg. 4, 197, 208).
The administration of physiological or even low
pharmacological doses of CORT does not replicate the
effects of endogenous glucocorticoid on the adrenal
medulla. Exogenously-administered CORT, which primarily
supplies the peripheral blood, does not restore CA
activity in the adrenal medulla after hypophysectomy
(208). ACTH, which enhances both the concentration of
glucocorticoids perfusing the adrenal medulla and
circulating in the periphery, does (83, 207, 208).
Enhancements in adrenal medullary CA enzyme activity,
particularly PMNT, are produced by DEX (198, 207, 208)
indicating this synthetic glucocorticoid actually
represents endogenous CORT's action at the adrenal medulla
more accurately than does exogenous CORT itself.
Experiments
In Experiment 1 and 2, the effects of the
administration of CORT and of DEX on the obesity produced
by PVN knife cuts were compared.
The steroids were administered to rats that still
possessed their adrenals. This contrasts the approach
typically taken in endocrinology studies. The traditional
paradigm involves the removal of a gland followed by
hormone replacement therapy. This approach was not
utilized in these studies for several reasons. The adrenal
is a multi-structural, -functional gland that modulates
the levels of glucocorticoids, mineralocorticoids and
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adrenomedullary CAs. The replacement of glucocorticoids
alone following adrenalectomy would not restore all three
aspects of adrenal function. Thus the responses
subsequently seen would not solely relate to the action of
glucocorticoids. Furthermore, removal of the adrenals
subsequent to severing CRF fibers, which is already
associated with deficits in adrenocortical functioning,
would introduce a confusing redundancy. Thus it would not
serve as a cogent argument for the participation of the
adrenals in the PVN obesity syndrome. To assess the role
of the adrenal medulla in paraventricular hypothalamic
obesity, it was necessary to use animals possessing
adrenals. This permitted the induction of adrenomedullary
CA activity by DEX. There is no known surgical technique
for removal of the adrenal cortex that will leave the
medulla intact and innervated.
In Experiment 3, the effect of DEX on appetitive
responses was further examined. To determine whether DEX
acts on appetite primarily via the adrenal medulla , DEX
was administered to knife cut and sham-operated rats after
adrenal demedullation.
36
CHAPTER II
EXPERIMENT I
In Experiment 1, rats with bilateral knife cuts
alongside the PVN received chronic treatments of CORT, or
DEX, or the control treatment. The purpose of this study
was to determine if CORT, the rats' natural
glucocorticoid, or DEX, a synthetic glucocorticoid, affect
the body weight and food intake of these rats.
Methods
Sixty adult female Charles River CD albino rats
were maintained in stainless steel hanging wire cages
under a 12:12 light: dark cycle and were provided unlimited
access to Purina Laboratory Chow (# 5001) pellets and tap
water
.
Phase One of Hormone Exposure
One day prior to surgery the rats were divided into
groups balanced for initial body weight. Naso-anal lengths
in millimeters (mm) were measured using a "stretch"
technique as described previously (50). The animals then
received either a moderate corticosterone dose (MCORT), a
high corticosterone dose (HCORT), dexamethasone (DEX), or
control treatments consisting of no hormone (NH) or
cholesterol (CH)
.
Corticosterone (Sigma Chemical Corp., St. Louis,
MO.) was administered as a solid pellet implanted
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subcutaneously in the nape of the neck. Pellets were
formed of molten solid hormone alone, the 100%
corticosterone pellet (HCORT dose), or of hormone and
cholesterol combined to form a 50% corticosterone pellet
(MCORT dose) . Cholesterol pellets served as control
implantations. Details of the procedure involved in making
these pellets are found in (121). The HCORT and MCORT
pellets supplied respectively an average dose of 1.58 +
0.20 mg CORT/day and 0.52 + 0.03 mg CORT/day (or -6.2
mg/kg and --2.0 mg/kg with respect to initial body
weights )
.
Animals treated with DEX (Sigma Chemical Corp., St.
Louis, MO.) received it via their drinking water. The day
prior to surgery all DEX-treated rats had access to 1
ug/ml of DEX in their drinking bottles. After surgery, DEX
was diluted to a concentration that allow each rat to
consume approximately 0.1 mg/kg/day (approximately 0.71
ug/ml for knife cut rats and 0.34 ug/ml for sham-operated
rats). The DEX dosage for each rat was adjusted daily for
the first six days after surgery, thereafter every third
day. It was calculated respective to the previous 1 day or
3 day average intake of water, and the current body
weight. These adjustments corrected for the large
differences in water intake that typically exist between
sham-operated and hypothalamic knife cut animals. The 0.1
mg/kg dose was administered through Day 18 post-surgery
(Phase One of Hormone Exposure). The protocol after Day 18
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is described separately
.
Stereotaxic brain surgery was performed with the
rats under ether anesthesia and consist of bilateral
parasagittal knife cuts alongside the PVN using a
retracting wire knife as detailed in (48). Briefly, the
parasagittal knife cuts were + 0.9 mm from the midline,
extended between 5 and 8 mm anterior to the interaural
line, and 3 mm dorsal from the base of the brain. Sham
surgery excluded extension of the retractable wire knife.
To summarize, the experimental groups were as
follows: sham-operated rats treated with either no hormone
(SH-NH, n=5), cholesterol (SH-CH, n=5), DEX (SH-DEX, n=8),
MCORT (SH-MCORT, n=6), or HCORT (SH-HCORT, n=6 ) ; and knife
cut-operated rats treated with no hormone (KC-NH, n=5),
cholesterol (KC-CH, n=5), DEX (KC-DEX, n=8), MCORT (KC-
MCORT, n=6), or HCORT (KC-HCORT, n=6). No differences
resulted between the NH or CH groups within surgery
manipulations, so these groups were collapsed (SH-CON,
n=10 and KC-CON, n=10).
On the day of surgery the rats were switched from
Purina Laboratory Chow pellets to Purina Mouse Chow
(#5015) pellets which provide a higher percentage of fat
(11%) in the diet. This diet promotes excessive weight
gain in PVN KC rats (46). Body weight, water intake, and
food intake corrected for spillage were measured.
After approximately 18 days of DEX exposure, a few
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KC rats exhibited a rapid elevation in water Intake and
began gnawing (which consisted of eating and/or spilling)
large amounts of food, which are indicative of a diabetic
condition. At this time urine samples were analyzed for
glycosuria using Tes-tape Glucose Enzymatic (Eli Lilly &
Co.) test strips.
Phase Two of Hormone Exposure
After 18 post-surgery days additional dosage and
hormone manipulations were performed.
First, employing the principles of an ABA design the
SH-DEX and KC-DEX groups were switched from 0.1 mg/kg/day
DEX to a 0.01 mg/kg/day maintenance dose for the period
from Day 18 to Day 39. This manipulation provides
information to confirm whether the lower weight gain seen
in KC-DEX rats was due to inadequate brain surgery, and to
determine whether the reduced weight gain under DEX was
permanent or transitory. The maintenance dose was needed
rather than no drug because DEX treatment atropies the
adrenal cortex via negative feedback inhibition of ACTH.
At Day 39, all rats were returned to their original dose
of DEX. This step also provides a test of whether the DEX
effects were coincident only with the initial 'dynamic'
post-surgery weight gain.
Second, 2-3 rats from each CON or CORT treatment
group were given 0.1 mg/kg/day DEX via their drinking
water in addition to their CH or CORT pellet implants.
The combined hormone treatment was employed to determine
40
whether the suppressive effects of DEX occurred by the
suppression of endogenous CORT secretion. On Day 27 these
SH-MCORT, -HCORT and KC-MCORT, -HCORT rats were removed
from the DEX-treated water and returned to tap water until
the end of the experiment.
On Day 36 post-surgery, naso-anal lengths were
taken again on all animals. While subjects were still
under ether anesthesia from this procedure, CORT pellets
were replaced and CH pellets were removed.
Blood Glucose Samples
At the end of the experiment (Days 48-51), blood
samples were collected prior to 'lights off. Samples
were taken from the tip of the tail into microhematocrit
tubes and centrifuged. The serum samples were stored in
microcentrifuge tubes, and frozen. Samples were assayed
for glucose with a YSI Model 23A Glucose Analyzer (Yellow
Springs Instrument Co., Yellows Springs, Ohio) using a
glucose oxidase method.
Naso-Anal Lengths and Obesity Indices
The Lee Obesity Index (86) was computed for each
animal from naso-anal length and body weight measures
taken just prior to surgery and again approximately 36
days after surgery. The formula for calculation of obesity
indices is (10^) N/sody weight (g)
Naso-anal length (mm).
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Surgical Verification
Two measures were utilized to verify the functional
accuracy of the knife cuts.
In the Initial 24 hour period after receiving
parasagittal knife cuts animals had to exhibit food Intake
at least 20% In excess of preoperative rates.
Examination of the brain of KC rats was performed
by making a series of coronal sections of formalin fixed
brains with a scalpel or razor blade and inspecting the
brain sections under a 20X Zeiss operating microscope
(OpMi-9, West Germany). Our laboratory has found that in
order to obtain rapid weight gains, knife cuts must be
alongside the PVN, must extend to the base of the brain,
and must be between 0.6 and 1.2 mm from the midline (48).
Data for animals which do not meet both the
behavioral and anatomical criteria were excluded from the
analyses. Based on these criteria a single rat from the
KC-CON group was excluded. Also omitted were the data from
a KC-DEX rat that contracted a respiratory infection and
was discovered upon autopsy to have an abdominal abscess.
Data Analysis
Data matrices were established and stored in the IDAP
system (Interactive Data Analysis Package, University of
Massachusetts, Amherst). IDAP system commands were
utilized to perform one- and two-way ANOVA, and comparison
tests such as the multiple range Duncan test. BMDP4V and
BMDP2V program packages (University of California, L.A.)
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were utilized to perform 2-way ANOVA and 2-way repeated
measures ANOVA analyses where appropriate.
Results
Phase One of Hormone Exposure
Body weight. A repeated measures analysis of variance
(ANOVA) of the cumulative body weight change over the
first 18 post-surgery days revealed significant main
effects for surgery (F( 1 ,49 ) =473 . 3 , p<.05) and hormone
(F( 3, 49) =80. 8, p<.05) and a significant surgery by hormone
interaction (F( 3 , 49 ) =13 . 9 , p<.05). The within varible of
body weight change across days was also significant
(F( 7, 343) =339. 5, p<.05) and interacted with both hormone
(F(21,343)=46.5, p<.05) and surgery factors
(F(7,343)=136.6, p< .05)
.
Chronic exposure to CORT via implanted pellets did
not substantially alter body weight. The cumlative body
weight change of sham-operated rats treated with either
the 50CORT or lOOCORT pellets did not differ significantly
from that of the sham-operated controls (Day 18, Figure
3 ) . The data suggest that exposure to CORT has a modest
inhibitory effect on the weight gain induced by PVN KCs.
By Day 18, KC rats exposed to HCORT had gained
significantly less cumulative weight than KC rats treated
with CON (multiple range Duncan comparison test, p<.05).
The response of KC rats exposed to the smaller MCORT dose
was intermediate, but not significantly different from
Figure 3. Mean body weight change of sham-operated
and PVN KC rats treated with no hormone (CON), 0.1
mg/kg
DEX, or a moderate (MCORT) or high (HCORT) dose of CORT
for 18 days after brain surgery (Phase One of Hormone
Exposure) . Between Days 21 - 48 (Phase Two of Hormone
Exposure), these rats experienced either the continuation
of their original CON or CORT treatment only (solid lines),
the combination of their original CON or CORT treatment plus
0.1 mg/kg DEX for nine days (Days 18-27, dotted lines)
followed by exposure to only CON or CORT ' (Days 27 - 48,
dashed lines), or the reduction of their DEX dose to 0.01
mg/kg for three weeks (Days 18-39, dashed lines) followed
by the reinstatement of the original 0.1 mg/kg DEX dose
(Days 39 - 48, solid lines). See Tables 4 - 6 for the
number of animals in the subgroups in Phase Two.
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either of the other two KC groups. However, it is
difficult to accept the validity of this experimental
finding as much of the difference between these group
means is attributable to one HCORT-treated KC rat which
exhibited an 45 g weight loss around Day 6. Furthermore,
comparing only KC rats treated with CON, MCORT, or HCORT,
a significant hormone factor did not emerge from a one-way
ANOVA of the cumulative weight change across Phase 1. Also
no differences were found between the absolute body weight
change of KC rats exposed to CON, MCORT, or HCORT over the
last 3 or last 6 days of Phase !•
In striking contrast to the minimal effects of CORT,
the administration of DEX inhibited the excessive weight
gain that typically accompanies PVN KC surgery. By Day 18
post-surgery, the cumulative weight change of KC rats
treated with 0.1 mg/kg DEX was significantly less than all
other KC groups (p<.05) and was comparable to sham-
operated rats treated with CON or with either dose of
CORT. DEX also greatly diminished the body weight of the
sham-operated rats beginning on Day 3 post-surgery and
continuing through Day 18 (versus all other sham-operated
groups
, p< . 05 )
.
Food intake. An overall ANOVA of the mean food intake
of rats over the initial 18 day experimental period
revealed significant surgery (F( 1,50) =468. 8, p<.05) and
hormone (F( 3 , 50 ) =20 . 9 , p<.05) main effects along with a
significant surgery by hormone interaction (F( 3 , 50 ) =7 . 0
,
p<.05). The within variable effect, mean food intake
across days, was significant (F( 7 , 350 ) =9 • 8 , p<.05) and
also interacted with the surgery (F( 7 , 350 ) =7 . 3 , p<.05),
but not the hormone, factor (Figure 4).
A small but statistically significant reduction in
total mean daily food intake emerged between KC treated
with HCORT and the KC rats given no hormone (p<.05). This
parallels the differences in body weight noted. However, a
repeated measures ANOVA of mean daily food intake across
Phase 1 comparing only KC rats exposed to CON or MCORT or
HCORT did not reveal a significant main effect for
hormone. The food intake of sham-operated rats was not
influenced by CORT at either dose.
DEX treatments produced a 74% reduction in the
hyperphagia of KC rats. Though the amount of food consumed
by DEX-treated KC rats was significantly less than eaten
by the other KC groups (p<.05), it was still more than
consumed by the sham-operated groups (p<.05). Exposure to
DEX did not alter the average quantity of food consumed by
sham-operated rats during Phase 1, but the DEX-treated
sham-operated rats did tend to eat less food than other
sham-operated rats early in the treatment phase. This
trend is compatible with the significant main effect for
hormone treatment seen in a one-way repeated measures
ANOVA that compares the main daily food intake of all
sham-operated groups across Phase 1 (F( 3 , 26 ) =5 . 81 , p<.05).
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Urinalysis
.
Urinalysis for glucose was performed on
subjects on or about Day 18 at the conclusion of phase 1
of hormone exposure. The presence of glucose In urine was
detected only In KC rats treated with 0.1 mg/kg DEX. It
was found in 4 of 7 rats in this group.
Phase Two of Drug Exposure
Combined administration of CORT plus DEX . When
subgroups were exposed to 0.1 mg/kg DEX via the drinking
water in addition to their initial CON, MCORT, HCORT
hormone treatment, decreases in body weight and food
intake similar to those seen with DEX alone were observed
in both sham-operated and KC rats, despite the
availability of CORT (Figure 3, dotted lines; Table 4 and
5) .
When DEX treatments were discontinued nine days
later, rapid gains in food intake and body weight were
seen in all subgroups (Figures 3 and 4, dashed lines;
Table 4 and 5 )
.
DEX produced glycosuria in several KC rats but never
in any sham-operated rats. In addition, KC rats treated
with exogenous CORT plus DEX did not show a greater
incidence of this condition than KC-CON rats treated with
DEX.
Reduction in DEX dose. The reduced DEX dosage was
coincident with increased body weight in both KC and sham-
operated groups (Figure 3, dashed lines). The rate of
weight gain of KC rats while treated with 0.01 mg/kg DEX
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was 8.1 + 0.7 day. This is reminiscent of the weight gain
of the KC-CON rats which had been 12.4 + 0.7 g/day from
brain surgery to Day 18 and 5.5 + 0.6 g/day between post-
surgery Days 18 to 39. Sham-operated rats rebounded to
gain weight at a rate of 3.1+0.4 g/day when treated with
the 0.01 g/day maintenance dose of DEX. This compares with
the 2.6 + 0.3 g/day and the 1.9 + 0.2 g/day weight gain of
sham-operated CON-treated rats between Day 1-18, and 18-
39 , respectively
.
A significant elevation in mean daily food intake was
seen in DEX-treated KC rats upon switching to the lower
DEX dose (Figure 4, dashed lines) such that their intake
did not significantly differ from any other KC group (KC-
DEX rats. Mean Daily Food Intake: Day 1-18, 28.7 + 1.6g;
Day 18-39, 32.9 + 1.8 g; correlated t(6)= 4.07, p<.05).
The amount eaten by DEX-treated sham-operated rats did not
differ from oths^r sham-operated treatment groups during
Phase 2, and it was slightly higher than the average
amount consumed by this group when administered 0.1 mg/kg
DEX in Phase 1 (SH-DEX rats. Mean Daily Food Intake: Day
1-18, 17.1 + 0.7g; Day 18-39, 19.8 + 0.9 g; correlated
t(7)=4.20, p<.05).
On Day 21, 3 days after the switch to the maintenance
DEX dose, glucose was detected in the urine of 2 of 7 rats
in the KC-DEX group, but was not revealed in this group at
any subsequent time through Day 39. Its presence was not
seen in any other treatment group from Day 18 to 39.
Reintroduction of the initial DEX dosage, 0.1 mg/kg,
to DEX-treated groups on post-surgery Day 39 decreased
both the body weight and food intake of KC and sham-
operated rats (Figure 3 and 4).
Glycosuria was noted in almost all KC rats, but no
sham-operated rats, treated with 0.1 mg/kg DEX during this
final experimental period. Days 39-48.
Continued exposure to CORT . The remaining sham-
operated and KC rats were maintained on their original
treatments of no hormone (CON), MCORT, or HCORT through
Day 48.
No profound changes in the weight gain response of KC
or sham-operated rats were seen with the continued
exposure to CORT during Phase 2. Although not readily
apparent in Figure 3 depicting cumulative body weight
gain, the absolute change and the rate of change in body
weight of rats treated with CON, MCORT, HCORT within each
surgery overlapped (Table 6).
Blood Glucose
Long-term exposure to neither CORT nor DEX altered
the blood glucose levels of sham-operated rats (Table 7).
The blood glucose values of the KC groups receiving CORT
or CON were slightly, sometimes significantly, higher than
for sham-operated groups. DEX treatments, however, caused
a marked elevation in blood glucose in KC rats. The mean
level of serum glucose of KC rats treated with 0.1 mg/kg
DEX was 3.3-3.6 times greater than any other experimental
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group
.
Naso-anal Length and Obesity Indices
Because the rats underwent a series of experimental
treatments prior to these measurements, the obtained
values represent a gross assessment of the effects of
experimental treatments on NA and OBI. Diminished linear
growth was seen in both sham-operated and KG subjects
chronically treated with DEX, but not in those treated
only with CORT (Table 8). Even the subgroup (n=2) of rats
that experienced a brief nine day exposure to DEX in
combination with their long-term CON or CORT treatments
were shorter than counterparts never exposed to DEX,
Regardless of hormone treatment KC groups had higher
obesity indices than sham-operated groups (Table 9).
Glucocorticoid treatments tended to lower obesity indices,
affecting KC rats more than sham-operated rats. Exposure
to DEX diminished obesity indices the most, followed by
exposure to HGORT.
Discussion
This experiment reveals that the glucocorticoids
CORT and DEX differ in their effects on the conSummatory
responses of PVN KG rats. The hyperphagia and excessive
body weight gain of rats receiving KGs was not
substantially altered by the CORT within a wide dose
range, 0.5 to 1.6 mg/day. Neither did CORT at these doses
influence the body weight or food intake of sham-operated
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rats« This held even when exogenously-applied CORT was
available continuously for 48 days. In contrast, DEX
attenuated the weight gain and the enhanced food intake
subsequent to KCs alongside the PVN. Exposure to DEX also
decreased the weight of sham-operated rats, but without
dramatic reductions in food intake.
The suppression by DEX of the hyperphagia and obesity
coincident with KC surgery was not permanent. When the
dose of DEX was reduced by a factor of 10, a rapid
increase in body weight and an elevation in food intake
were observed. However, the rate of body weight gain of KC
rats treated with maintenance 0.01 mg/kg DEX (8.1 g/day)
did not reach the magnitude seen in controls after KC
surgery (12.1 g/day) nor did the food intake of the DEX-
treated KC group equal the levels seen in other KC
subjects immediately after surgery. This may be due to
residual effects of DEX, to the later point in time after
surgery at which this manipulation occurred, or to the
0.01 mg/kg dose of DEX.
The diminished weight gain produced by DEX in sham-
operated rats was also transitory. Interestingly, the
compensatory body weight response of sham-operated rats
upon reduction of the DEX dose occurred without a dramatic
increase in food intake. This suggests that DEX's
influence on body weight is not tied to food intake alone,
but may encompass underlying metabolic changes.
The suppressive effects of DEX on the ingestive
59
responses of KC rats were not limited to the initial or
'dynamic' post-surgery weight gain. DEX administered when
the weight gain began to plateau still yielded decrements
in body weight and food intake.
The treatment of KC rats with 0.1 mg/kg DEX was
associated with glycosuria. This condition could not be
attributed solely to DEX because glycosuria was never seen
in DEX-treated sham-operated rats. Glycosuria also didn't
necessarily relate to the administration of exogenous
glucocorticoids per se, because it was not seen in KC rats
on CORT. Furthermore, the amount of urinary glucose in KC
rats was not enhanced by simultaneous CORT and DEX. Thus,
the emergence of this condition is tied to elements
related to KCs alongside the PVN and the glucocorticoid
DEX. It also appears to be a function of elevated
circulating glucose levels as only DEX-treated KC rats had
greatly elevated levels of plasma glucose. The glycosuria
disappeared in the DEX-treated KC rats with the change
from the 0.1 to 0.01 mg/kg dose of DEX indicating this
condition was reversible. Reversibility has been
recognized previously as a characteristic of steroid-
induced diabetes (100).
The excretion of calories that accompanies exposure
to DEX may contribute to the reduced weight and naso-anal
lengths of KC rats, but cannot account for these
characteristics in DEX-treated sham-operated rats. Thus
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other aspects of DEX's action must also contribute.
The central finding of this experiment was that the
glucocorticoid CORT and DEX differentially influence the
regulatory responses of rats after KC or sham brain
surgery . Several factors may account for this outcome.
First, CORT possesses mineralocorticoid properties, while
DEX doesn't (60, 55, 63, 122). The absence of
mineralocorticoid effects by the steroid DEX could have
contributed to decreases in body weight and food intake.
However when DEX was administered jointly with CORT, which
would contribute mineralocorticoid effects, the
suppressive effects of DEX were still seen. This suggests
that an absence of the mineralocorticoid properities were
not crucial.
Other differences between CORT and DEX in their type
or site of action may explain the incongrous results
produced by these steroids. For example, the site(s) at
which each steroid produces the greatest negative feedback
action differs (eg. 156, 157). CORT and DEX have also been
noted to differ in the potency of their glucocorticoid
function (eg. 60, 63, 122, 195). comparison to
exogenously-applied CORT, DEX better replicates the action
of endogenous intraadrenal corticosterone on CA synthesis
in the adrenal medulla (208). It is this latter disparity
in action that was postulated to be of significance in
examining PVN KCs and the functional status of the
adrenal
gland. Each of these disparities between CORT and
DEX will
be further addressed in subsequent sections.
Last, the differing routes of administration employed
for CORT and DEX in this study may account for their
contrasting regulatory responses* This possibility was
tested in Experiment 2.
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CHAPTER III
EXPERIMENT II
in Experiment 1, the administration of DEX, but not
CORT, attenuated the excessive weight gain and hyperphagia
typically seen subsequent to knife cuts alongside the PVN.
The purpose of Experiment 2 was to verify and to further
characterize the results obtained in Experiment 1.
The present experiment first tried to establish
that CORT's inability to block PVN knife cut-induced
obesity was not peculiar to the subcutaneous route of
administration employed for CORT. In Experiment 2 both
hormones was administered via the drinking water. This
also allowed the steroids to be supplied in an
approximation of the rats' circadian rhythm.
Experiment 2 also included the administration of
these steroids in incremental dose phases to demonstrate
dose-response relationships.
General Methods
Thirty adult female 200-240 g Charles Rivers CD
albino rats were individually housed in hanging
stainless
steel wire cages and exposed to 12:12 hour lightidark
conditions. Purina Laboratory Chow (# 5001) pellets
were
available ad libitum until the time of surgery.
After
surgery rats were switched to ad libitum Purina
Mouse Chow
(# 5015) pellets. Drinking water was
available without
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restriction.
Hormone treatment began one day prior to surgery.
Dexamethasone (DEX) or corticosterone (CORT), or a no
hormone control (CON) (vehicle only) was given via the
drinking water. Rats within each hormone treatment group
received either sham operations or bilateral symmetric
parasagittal retracting wire hypothalamic knife cuts as
described in Experiment 1. The stereotaxic coordinate for
the KC surgery was A8.2 mm (anterior to the earbars); L9.0
mm; V7.0mm. From this point, the wire knife was extended
caudally, except in the sham manipulation, and the
assembly was lowered approximately 3 mm until it contacted
the base of the skull. At the conclusion of the
experiment, one rat from the KC-DEX treatment group was
determined to have a misplaced KC and was excluded from
the experimental analyses.
Each hormone was dissolved in 100% ethanol. Daily
water intakes and body weights were monitored. The
hormone
doses were adjusted daily to the scheduled doses. Doses
were calculated with regard to the previous days'
water
intake and the current body weight. The drinking.
water
solution was made by micropipetting the appropriate
volume
of a concentrated stock ethanol-hormone
solution into the
appropiate volume of fresh water.
Experimental Phases A-D
The experimental groups were exposed to
successive
dosage increments. Each dose was given for
6-7 days, in
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accordance with the relative potencies of these sterlods,
the dose series of CORT administration was 4, 8, 16, 32
mg/kg/day (Phase A, B, C, D, respectively) and that of DEX
was 0.05, 0.1, 0.2 mg/kg/day (Phase A, B, C,
respectively). In addition to the measurement of body
weight and water Intake, rats' food Intake was determined
with adjustments for food spillage.
Treatment with glucocorticoids, particularly DEX, can
produce a glycosuric condition. KC animals treated with
DEX appear to be especially susceptible. To better
establish the factors associated with the presence and
the
pattern of this condition, the presence of glucose
in the
urine was closely monitored in this experiment.
Urinalyses
for glucose were performed on the third and last
day of
each dose exposure phase. To collect a urine
sample, an
animal was removed from its home cage and
placed in a
clean, empty wire mesh cage which rested over
a clean
piece of cellophane plastic wrap. Typically
within 3-10
minutes, an animal urinated providing a testable
sample on
the cellophane. If a considerable amount of
time passed
without obtaining a sample, to encourage
urination, a
subject was handled briefly. Urine glucose content
was
measured using Dlastlx Reagent Strips (Ames
Division,
Miles Laboratory, Indiana).
Blood Glucose Samples
day 6-7 of each hormone dose exposure
phase, blood
On
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samples were taken from restrained, unanesthesized rats.
Beginning 1/2 hour into the light phase, animals were
taken from the animal room into an outer room. Here blood
samples were drawn from the tip of the tail into a
microcentrifuge tube. The tubes were then be centrifuged,
and plasma serum samples were separated and frozen for
later analysis. Plasma serum was measured for for blood
glucose levels.
Saline Test
Several factors suggest that DEX may influence the
status of the fluid and/or electrolyte balance of an
animal to produce its effects. In contrast to CORT which
possesses mineralocorticoid properities in addition to its
glucocorticoid actions, DEX possesses no mineralocorticoid
properities. Also, at higher doses DEX suppresses the
adrenal cortex which might compromise endogenous
mineralocorticoid secretion. Finally, knife cuts alongside
the PVN disrupt vasopressin neurons which would
also
compromise water conservation. This surgery in
combination
with DEX treatment may therefore synergistically
disturb
the water and /or electrolyte balance of an
animal.
TO examine the possible contribution of
these
factors, a saline solution exposure test was
performed.
This test was conducted from the second
to the fifth day
of the dose phase when rats were treated
with either 0.2
mg/kg DEX or 16 mg/kg CORT or the control, CON.
In
addition to their drinking water bottles,
the rats were
given a 2% saline solution. A strong salt-tasting solution
was used so that rats which were not in need of salt for
homeostatic balance would avoid it; whereas, rats in need
of sodium would exhibit an affinity. Intakes of the saline
and water solutions were measured daily.
Experimental Phase D-E
Insulin test . In the present experimental protocol
the occurrence of glycosuria tended to be unique to KC
DEX-treated rats. This manipulation was performed to study
the responsiveness of this hormone- induced condition to
insulin.
The subjects utilized were the SH- and KC-DEX
treatment groups from the previous phases, A-C. These two
groups were maintained on 0.2 mg/kg/day of DEX, which was
a continuation of their 7 day exposure to this dose in
Phase C. The rats received daily subcutaneous injections
of long-acting Lente insulin zinc suspension (E. R. Squibb
& sons, inc., Princeton, N. J.). Insulin was administered
just prior to lights off at a dose of 5 U/kg for 6 days,
followed by a dose of insulin of 8 U/kg for 6 days. On the
final day of exposure to each dose, blood samples were
obtained for glucose analysis. Body weight, food intake,
and water intake were recorded. Urinalyses for the
presence of glucose were performed.
Adrenal Gland Weights
At the end of the experimental testing period,
the
adrenal glands of all subjects were removed, dissected
of
peripheral fat tissue, blotted, and weighed to the nearest
0.001 g. Prior to this procedure, animals experienced at
least 9 days of exposure to their respective hormone
treatments at the dosage levels of 16 mg/kg CORT, 0.2
mg/kg DEX, or the CON water control.
Naso-anal Lengths and Obesity Indices
When rats were under ether anesthesia upon removal of
their adrenals their final naso-anal lengths were
measured. The final obesity indices of the rats were
determined
.
Results
Phase A
in treatment phase A, the doses of DEX and CORT were
respectively 0.05 mg/kg and 4 mg/kg.
Body weight. Analysis of variance of the absolute
and the percentage body weight change during this phase
reveals a significant main effect for surgery (Absolute:
F(l,23)=382.9, Percentage: F( 1 , 23 ) =300 . 0 , p<.05) and
hormone treatments (Absolute:F( 2 , 23 ) =9 . 06 , Percentage:
F(l,23)=6.9, p<.05) (Figure 5).
The body weight gain of neither KC nor sham-operated
rats was altered by exposure to CORT. in contrast,
DEX
attenuated weight gain. For the sham-operated rats
this
difference was not statistically significant and
may
reflect an extreme response of one rat. A
significant
reduction was seen in both the absolute and the
percent
68
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Surgery
Days After Surgery
70
Figure 5. Mean body weight change of
sham-operated
and PVN KC rats treated with either no
'
4, 8, 16, and 32 mg/kg CORT across Phases
A - D respectively,
or 0.05, 0.1. 0.2 mg/kg DEX and 0.2 mg/kg
DEX plus 5 U/kg
insulin across Phases A - D, respectively.
69
body weight gain of PVN KC rats treated with 0.05 mg/kg
DEX (Duncan, p<.05). These rats gained approximately 66%
of the weight gained by CORT- or CON-treated rats after
PVN KC surgery.
Food intake. During the first treatment phase the
mean food intake of rats with PVN KCs was significantly
greater than that of rats experiencing only sham brain
surgery (Surgery: F( 1 , 23 ) =529 . 0 , p<.05). Exposure to the
0.05 mg/kg DEX or 4 mg/kg CORT had no significant effect
on the food intake of any surgery group (Figure 6).
Water intake. PVN KC surgery produced a large
elevation in water intake (Surgery: F( 1,23) =68. 9, p<.05).
Neither hormone treatment produced any additional changes
in water intake (Figure 7).
Urinalysis. Glucose was not detected in the urine
of any rats during this phase.
Phase B
During the second treatment phase the doses of CORT
and DEX were doubled to 8 mg/kg CORT and 0.1 mg/kg DEX.
Body weight. A significant main effect for surgery
and hormone treatment, along with a significant surgery by
hormone interaction, resulted for body weight in Phase B
(Absolute - Surgery: F( 1 , 23 ) =98 . 3 , Hormone: F( 1 , 23 ) =46 . 3
,
Surgery x Hormone: F( 2 , 23 ) =15 . 3 , p<.05; Percentage
-
Surgery: F( 1 , 23 ) =64 . 3 , Hormone: F( 2 , 23
) =43 . 6 ; Surgery x
Hormone: F(2,23)=7.0, p<.05) (Figure 5).
During this phase the weight gain of PVN KC rats
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exposed to DEX declined to match that of sham-operated
rats treated with CORT or CON. The weight gain of sham-
operated rats exposed to DEX was also suppressed (p<.05).
PVN KC rats on CON or CORT continued to gain weight
in excess of all other groups (p<.05). Although CORT
treatments did not influence the weight gain of sham-
operated rats, PVN KC rats exposed to 8 mg/kg CORT
significantly outgained the vehicle-treated KC group
(p<.05). This holds when weight gain is expressed as
absolute weight change or as a percent. The potentiated
weight gain of PVN KC rats exposed to CORT continued into
the first five days of the 'break' period (p<.05), a time
when hormones were still available. But in the following
2 days in this 'break' period when no hormones were
administered the KC-CORT and KC-CON groups did not differ
in their weight gain.
Food intake. During this second treatment phase
(post-KC surgery days 7-14), PVN KC rats continued to
consume significantly more food than sham-operated
subjects (Surgery: F( 1 , 23 ) =180 . 9 , p<.05) (Figure 6).
Hormone treatments influenced food intake (Ho.rmone:
F(2,23)=3.6, p<.05). DEX-treated rats with PVN KCs ate
significantly less than the CON- or CORT-treated with PVN
KCS (p<.05), but they still overate (p<.05, versus sham-
operated groups).
water intake . PVN KC rats continued to consume
more
water than sham-operated rats (Surgery: F( 1 , 23
) =53 . 9
,
p<.05). KC rats treated with CORT drank significantly
more water than KC rats treated with vehicle (p<.05), but
not more than KC rats treated with DEX (Figure 7). In
turn, the water intake of DEX-treated rats with PVN KCs
was not significantly different from that of PVN KC
controls
.
Urinalysis . Glycosuria was detected in the last three
days of this phase in 3 of 4 PVN KC rats treated with DEX.
The amount of glucose present in urine on any given day
ranged from +1/4 % (2 rats) to +1 % (1 rat) which
represent concentrations of 250 mg/dL and 1000 mg/dL,
respectively. No glucose excretion was detected in DEX-
treated sham-operated rats nor any rats treated with CON
or CORT.
Phase C
In treatment phase C, experimental groups treated
with CORT received a dose of 16 mg/kg, and those treated
with DEX received a dose of 0.2 mg/kg.
Body weight . A significant main effect for the
surgery and hormone conditions emerged from the analysis
of the absolute (Surgery: F( 1 , 23 ) =10 . 6 , Hormone:
P( 2, 23) =21. 6, p<.05) and the percentage (Surgery:
F(l,23)=6.4, Hormone: F( 2 , 23 ) =38 . 7 , p<.05) body weight
changes during this phase. A significant surgery X
hormone interaction was present for absolute body weight
change (Surgery x Hormone: F(2,23)=3.9, p<.05).
Exposure to 0.2 mg/kg DEX produced a steady decrease
in the body weights of PVN KC and sham-operated rats that
was significantly different from all other groups (p<.05).
As depicted in Figure 5, a significantly higher mean
cumulative weight gain was seen in PVN KC rats treated
with CORT than in KC rats in the CON treatment group in
Phase C (p< .05 )
.
Food Intake . Analysis of variance of the mean food
intake during Phase C revealed a significant main effect
for surgery (F( 1 , 23 ) =63 . 2 , p<.05) and hormone
(F( 2, 23) =9.0, p<.05) treatment conditions in addition to a
significant interaction (F( 2 , 23 ) =6 . 7 , p<.05) (Figure 6).
During Phase C, post KC surgery days 21-27, both CON-
and CORT-treated rats with PVN KCs were still hyperphagic
(p<.05). In contrast, the food intake of PVN KC rats
exposed to DEX was suppressed such that it was comparable
to the intake of the sham-operated controls. Neither of
the hormones administered during this phase altered the
food intake of sham-operated rats.
Water intake. The water intake response of rats
during this phase parallel the pattern seen in the
previous treatment phase (Figure 7). The water intake of
CORT-treated rats with PVN KCs was greater than that of
CON-treated KC rats (p<.05) but not DEX-treated rats.
urinalysis . Only PVN KC rats (n=4) administered 0.2
mg/kg DEX exhibited glycosuria. Glucose was present in
their urine intermittently throughout this phase in
concentrations ranging from 0 to 2% (or 2000 mg/dL). This
included one DEX-treated KC rat that was never glycosuric
and one that excreted a slight 1/10 % (or 100 mg/dL)
concentration of glucose on only one day.
Phase D
in treatment phase D, the dose of CORT administered
was increased to 32 mg/kg. The results of the
experimental manipulation performed on DEX-treated rats
during this period are discussed below.
Body weight . At the end of Phase D the mean
cumulative weight gain of PVN KC rats treated with 32
mg/kg CORT was significantly greater than the weight gain
exhibited by PVN KC rats receiving the CON treatment
(p<.05). However, a comparison of the actual or the
percent changes in weight that took place over this phase
did not reveal a significant difference between these PVN
KC groups. The body weight response of sham-operated rats
was not influenced by exposure to the 32 mg/kg CORT dose
(Figure 5 )
.
Food intake. From day 27-34 after PVN KC surgery
which constitutes Phase D of hormone treatment, rats with
PVN KCs still ate more than rats that underwent sham brain
surgery (Surgery: F(l,23)=37.4, p<.05) (Figure 6).
Whereas exposure to this pharmacological dose of CORT did
not alter the food intake of sham-operated rats, PVN KC
rats treated with 32 mg/kg CORT consumed significantly
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more food than their control counterparts (p<,05).
Water Intake , Only PVN KC rats exposed to CORT drank
in excess of sham-operated groups in Phase D (p<.05)
(Figure 7 )
.
Urinalysis > In this last phase, glucose was never
detected during urinalysis. Even the administration of
the pharmacological 32 mg/kg dose of CORT did not produce
glycosuria.
Phase D-E
Sham-operated and KC groups treated with DEX received
a dose of 0.2 mg/kg DEX during treatment phases D and E.
This hormone treatment was combined with insulin at a dose
of 5 U/kg/day in Phase D and of 8 U/kg/day in Phase E.
Insulin test . An overall analysis of variance
revealed that insulin influenced the body weight responses
produced by 0.2 mg/kg DEX (Absolute change: F(2,6)=37.4,
Mean change: F( 2, 6) =17.0, p<.05).
The administration of 5 or 8 U/kg/day of long-acting
insulin during Phase D-E arrested the weight loss seen in
sham-operated rats exposed to 0.2 mg/kg DEX (Bonforroni t-
test, adjusted family-wise error rate <.017), but it did
not reinstate a substantial weight gain in these rats
(Figure 8). In contrast, the food intake of sham-operated
rats treated with 0.2 mg/kg DEX was not significantly
altered by insulin (Figure 9). These rats ate the same
amount whether treated with DEX alone or with 5 U/kg
insulin plus DEX. However, the amount eaten in the 5
versus 8 U/kg treatment phases did differ (Bonforroni
adjusted t-test) . During this test period, sham-operated
rats treated with DEX increased their water intake (data
not shown) when insulin was administered in conjunction
with DEX (Bonforroni adjusted t-test). Finally urine
glucose was not detected in sham-operated rats when DEX
and insulin treatments were combined.
The decreases in body weight observed in KC rats
exposed to 0.2 mg/kg DEX were not significantly altered by
the addition of insulin at 5 or 8 U/kg. However, the data
suggest that insulin treatments may mitigate the DEX-
induced decreases in the body weight of KC rats to some
degree as some relevant group comparisons bordered on
statistical significance (Bonforroni adjusted t), and a
repeated measures analysis of variance revealed a
significant change between the phases of the insulin test
(F(2,2)=21.2, p<.05). Neither the food intake nor the
water intake (data not shown) of KC rats treated with 0.2
mg/kg DEX was significantly influenced by the
administration of 5 or 8 U/kg/day insulin. Lastly,
analysis of urine glucose revealed that insulin injections
did not alleviate the glycosuria seen in KC rats exposed
to 0.2 mg/kg DEX. Insulin may indeed potentiate this
condition.
Saline Test
The consumption of the 2% saline solution presented
80
70-
50-
2
o
c
o
30-
U
^ 20-
"O 10
o
CO
HO-
•30-
0J2mg/Kg Dex
a2mg/Kg Dex
+
sU/Kg Insulin
o.2mg/Kg Dex
+
sU/Kg Insulin
Insulin Test Days
1 234S6!l 23456
I I I I I I'l I I I I I
""V-i 1 r
21 24 27 30 33
Days After Surgery
36 39
Figure 8. Mean body weight change of
sham-operated and PVN KC rats treated with 0.2
mg/kg DEX alone in Phase C, followed by treatments
of this 0.2 mg/kg DEX dose in conjunction with
5 U/kg insulin in Phase D and with 8 U/kg insulin
in Phase E- Symbols are as indicated in Figure
5.
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M Control
Dex
Figure 9. Mean daily food intake of
sham-operated and PVN KC rats treated with
0.2 mg/kg DEX alone in Phase C, followed by
treatments of this 0.2 mg/kg DEX dose in
conjunction with 5 U/kg insulin (I) in Phase
D and with 8 U/kg insulin (1) in Phase E.
Mean daily food intake values for sham-operated
and KC rats exposed to no hormone (Control)
•during Phase C included for comparisons.
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during Phase C did not significantly differ between
experimental groups (Table 10). Although KC rats provided
DEX tended to consume less of the saline solution than
other rats did, this trend was not significant as
determined by a Duncan multiple range comparison test or a
nonparametric Mann-Whitney U test.
This provides evidence that exposure to these
glucocorticoids did not significantly disrupt electrolyte
balance, particularly with respect to Na+. It also
suggests that the differing mineralocorticoid properties
of CORT and DEX did not contribute to the different body
weight responses produced upon their administration. There
appears to be a tendency for saline intake to shift in a
counter-intuitive direction. CORT, with some mineralocoid
action, yielded the highest saline intakes, while DEX,
which has virtually no mineralocoid action, yielded the
lowest saline intake.
Blood Glucose
A slight elevation in blood glucose was seen in sham-
operated rats treated with DEX or with the high 16 and 32
mg/kg doses of CORT (Table 11).
Exposure to pharmacological doses of CORT did not
markedly alter the serum glucose levels of PVN KC rats,
but the availability of exogenous CORT maintained the
slightly potentiated glucose levels of KC rats beyond the
Initial 2-3 weeks after KC surgery.
At all doses DEX dramatically enhanced the amount of
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TABLE 10
MEAN INTAKE (ml ± SEM) OF A 2% SALINE SOLUTION PROVIDED
SHAM-OPERATED AND PVN KNIFE-CUT RATS EXPOSED TO
NO HORMONE (CON), CORT, OR DEX
DURING PHASE C OF EXPERIMENT TWO
SHAM: SALINE INTAKE
CON 12.4 ± 4.5
CORT 17.7 ± 6.5
DEX
KNIFE CUT
CON
CORT
DEX
11.2 ± 2.9
12. 7 + 2.2
23. 4 + 11.1
5. 2 + 1.4
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serum glucose in KC rats. This DEX-induced increase was
dose-related and reached as high as four times the glucose
levels of KC controls. As with glycosuria, there was large
individual variability within the DEX-treated KC group.
Adrenal Gland Weights
At the conclusion of the experiment and prior to the
removal of their adrenal glands, rats were exposed to a 16
mg/kg dose of CORT, or a 0.2 mg/kg dose of DEX, or CON for
approximately 9 days. Since other hormonal manipulations
preceeded this exposure, it serves best only as a general
assessment of how the dosages of glucocorticoids used here
influenced the adrenal glands (Table 12).
Significant surgery and hormone treatment effects
were found in the ANOVA for the weights of the right
adrenal gland (Surgery: F( 1,21) =11. 2, Hormone:
F( 2 , 21 ) =27 . 8 , p<.05) and the left adrenal gland (Surgery:
F( 1,21) =7. 9, Hormone: F( 2 , 21 ) =19 . 0 , p< .05) , and combined
weight of these glands (Surgery: F( 1,21) =9. 8, Hormone:
F(2,21)=23.9, p<.05)
.
KCs alongside the PVN alone significantly reduced
adrenal gland weights (p<.05). Exogenous treatments with
glucocorticoids also caused adrenal atrophy. The smallest
adrenal glands were seen in KC rats exposed to DEX or to
CORT, and in sham-operated rats exposed to DEX (p<.05).
The reduction in adrenal size produced by CORT alone is
comparable to that produced by KCs alone (p<.05).
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Naso-anal Lengths and Obesity Indices
Naso-anal length (NA) and obesity Index (OBI)
measures were determined after rats were exposed to 16
mg/kg CORT, 0.2 mg/kg DEX, or CON for several days (Table
13). Because the rats underwent a series of experimental
treatments prior to these measurements, the obtained
values represent a gross assessment of the effects of
experimental treatments on NA and OBI.
Chronic exposure to DEX, but not CORT, reduced NA
length. Each DEX-treated group was significantly shorter
than all other experimental groups (p<.05) with sham-
operated rats being attenuated more than KC rats by DEX
(p<.05).
Analysis of variance of OBI reveals a significant
interaction effect (Surgery x Hormone: F( 2 , 20 ) =20 . 0
,
p<.05). The obesity indices of sham-operated rats treated
with either CORT or DEX, and KC rats treated with DEX were
comparable to the normal weight of SH-CON control rats.
KC rats treated with CON and those treated with CORT had
elevated OBI values (p<.05). The extent of the elevation
seen in these two groups was similar, but the mean OBI
value of CORT-treated KC rats may not be accurately
represent this group. Because two of the heaviest KC rats
treated with CORT died prior to the determination of their
obesity indices, their data could not be included in the
calculation of this mean.
For the DEX-treated KC rats, the correction for
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TABLE 13
MEAN NASO-ANAL LENGTHS (mm ± SEM) AND MEAN OBESITY INDICES (± SEM)
FOR SHAM-OPERATED AND PVN KNIFE-CUT RATS CHRONICALLY EXPOSED TO
NO HORMONE (CON), CORT, OR DEX DURING EXPERIMENT TWO
SHAM : NASO-ANAL LENGTHS OBESITY INDEX
CON 227.2 ± 2.3 292.8 ± 7.9
CORT 224.4 ± 1»6 293.5 ± 1.7
DEX 210.5 ± 1.0* 289.6 ± 3.6
KNIFE CUT ;
CON 225.0 ± 2.1 364.7 ± 6.8+
CORT 225.0 ± 0 363.7 ± 3.4+
DEX 217.3 ± 0.95* 296.4 ± 6.0
* - differs from all other treatment groups, p<.05
+ - differs from all other treatment groups, but not each other,
p < .05
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shortened body length inherent in the OBI calculation
still resulted in less obesity than was observed for the
CON- and CORT-treated KG groups
.
Discussion
In the present study CORT and DEX were administered
via the same route of administration • The response to the
agents was similar to that seen in Experiment 1. This
indicates that the differential response elicited by these
hormones in Experiment 1 is not due to the route of
administration
.
DEX suppressed body weight at most doses used and
food intake at some of them, whereas CORT retarded neither
weight gain nor feeding. The synthetic glucocorticoid DEX
is typically cited as having anywhere from 5 to 80 times
the potency of CORT (60, 63, 122, 195). The potency
difference between these hormones does not appear to be
responsible for the differential responses produced by
them in this study. Even when 32 mg/kg CORT was
administered, which is 640 times the lowest (0.05 mg/kg)
effective DEX dose given, it did not attenuate body
weight, food intake, or water intake, nor did it ever
.
produce glycosuria. In fact, our data suggest that high
doses of CORT potentiate the weight gain of PVN KC rats,
as the cumulative weight gain of CORT-treated KC rats
exceeded all other KC groups. An elevation in food intake
was seen as well in KC rats exposed to the highest dose of
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CORT. Others have also found a potentiation of body
weight gain and food intake in rats following
hydrocortisone and corticosterone injections (57, 106).
In the sham-operated rats of the present study, the
administration of CORT at any dose, even high
pharmacological doses, did not alter body weight or
ingestive behavior. These sham-operated rats had reduced
adrenal weights which indicates the negative feedback
action of CORT was present.
A range of evidence clearly indicates that knife cuts
alongside the PVN disturb the capacity and response of the
pituitary-adrenocortical system (see Chapter I). This is
reflected by measures such as reduced adrenal weight (107,
109, this study), diminished levels of circulating
corticosterone (67, 109, 174), and lack of compensatory
increase in ACTH after adrenalectomy (108, 109). What is
unclear is whether and how deficits in the responsiveness
of the adrenocortical system contribute to the obesity
syndrome seen after disruption of the PVN. In the present
experiment, compensating for the adrenocortical
insufficiency by supplementing rats with CORT did not;
diminish the obesity that resulted after KCs alongside the
PVN. This finding suggests that the limitations in the
availability of circulating CORT that result from severing
CRF-positive paraventriculo- infundibular neural
projections do not directly underlie knife cut-induced
obesity.
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However, the presence of basal levels of
glucocorticoid hormone appears to be necessary for the
development of hypothalamic obesity because the
elimination of CORT via adrenalectomy prevents the obese
condition, while replacement therapy with CORT reinstates
it (26, 70). Taken together, this suggest that
circulating CORT plays a permissive, but not causative,
role in the expression of hypothalamic obesity.
In contrast, DEX curtailed body weight gain at a
range of dosages. The lowest (0.05 mg/kg) dose of DEX
attenuated the post-surgery weight gain of PVN KC rats by
approximately one-third without attenuating the body
weight of sham-operated rats. The reduction in weight
gain produced by 0.05 mg/kg DEX was not due to decreased
food consumption because food intake was not altered at
this dose even though plasma glucose levels were
augmented. Neither could it be attributed to the loss of
calories in the urine, as glycosuria was not detected
during this phase.
As a result, KC rats treated with 0.05 mg/kg DEX had
a lower feed efficiency than KC rats treated with CORT or
with CON (KC-DEX, -CORT, -CON: 0.064+ 0.007, 0.087 +
0.005, 0.087 + 0.004 g weight gain/kcal eaten). This
suggests an increased energy expenditure, most likely an
increase in the activity of the sympathetic nervous
system. The ability of DEX to enhance CA, particularly E,
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synthesis in the adrenal medulla may account for its
effects on body weight. Conversely, a compromise of
adrenal medullary function may contribute to the weight
gain seen after KCs alongside the PVN.
As the dose of DEX was increased to 0.1 and 0.2
mg/kg, reductions in body weight gain increased in knife
cut rats and emerged in sham-operated rats. The weight
loss observed in sham-operated rats at these higher doses
was not accompanied by declines in food intake nor by
excretion of glucose. The low feed efficiency in these
sham-operated rats again is consistent with potentiation
in sympathetic and/or adrenomedullary activity.
In contrast, the diminished body weights of PVN KC
rats during the higher doses of DEX treatment were
accompanied by decreases in food intake, elevated blood
glucose levels, and varying degrees of glycosuria.
Clearly, the relation between DEX treatment and body
weight in KC rats is encumbered by the occurrence of
glycosuria. However, this condition contributed minimally
at the 0.1 mg/kg DEX dose, being more prevalent at the 0.2
mg/kg DEX.
The glycosuria that occurred upon exposure to DEX was
again seen only in rats with PVN KCs. The condition was
not ameliorated by insulin, indicating that it is
extrapancreatic in origin. Glycosuria or so called
'steroid diabetes' has been noted previously with the
administration of glucocorticoids (55, 63, 100, 195).
This condition tends to occur in humans predisposed to a
diabetic-like state when they are treated with
glucocorticoids (195). Glycosuria has also been documented
after distruction of the hypothalamic paraventricular area
in rabbits and cats that are not even treated with
glucocorticoids (6, 28) and in VMH KC rats fed a palatable
diet high in fat and sugar (29). Thus, its occurrence only
in KC rats in this study may stem from other physiological
changes in carbohydrate metabolism associated with the
disruption of the PVN (eg. obesity) that act
synergistically with DEX.
Being a glucocorticoid, DEX is considered to increase
blood glucose by a range of metabolic processes including
hepatic glucose production, lipolysis, and hyperglycemic
hormones such as glucagon (19, 60, 100, 193). Although
not readily acknowledged, another source of DEX's glucose-
promoting effects may lie in its activation of
sympathoadrenal CAs. This is also significant in light of
the fact that glucocorticoids potentiate the effects of
other hyperglycemic hormones such as CAs and glucagon
(100, 38).
Extreme hyperglycemia induces hyperinsulinemia which
can in turn decrease glucose tolerance. Insulin secretion
in response to glucose in in vitro pancreas preparations
is reported to vary depending on the particular
glucocorticoid hormone present (100). The addition of
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CORT inhibits glucose- induced insulin secretion while DEX
does not. As elevated insulin levels are also
characterisitic of rats experiencing disruption of the PVN
(50, 170, 176), one can speculate that the combination of
DEX treatments and KC surgery may foster a state of
insulin resistance which would encourage high circulating
glucose levels and glycosuria. On the other hand, Lenzen
(100) suggests that increased insulin concentrations are
not fully involved in the precipitation of steroid
diabetes and indicates that the emergence of this
condition is "critically dependent on the functional
reserve of the endocrine pancreas". Perhaps KCs alongside
the PVN somehow also alter this aspect of pancreatic
function.
Differences also exist in the inhibitory action of
DEX and CORT at hypothalamic and pituitary sites. When
given at lower doses, CORT acts at the hypothalamus
reducing CRF, while DEX acts at the anterior pituitary
suppressing ACTH (156, 157). This difference could
underlie the incongruous consummatory responses these
steroids produce. Negative feedback at both the .
hypothalamic and anterior pituitary levels occurs with
relatively large doses of CORT or of DEX (157). This dual
feedback inhibition most likely takes place at the higher
doses of CORT used in the present study. However, for DEX
to inhibit both hypothalamic CRF and pituitary ACTH after
a 6 hour infusion period, amounts 5 to 10 times greater
than the highest doses used here were required (157). How
this relates to the chronic DEX exposure used in this
study cannot be certain, but it suggests that DEX acted
only at the anterior pituitary. Yet, in Experiment 1, when
rats were administered CORT in addition to DEX, no
deviations from the typical suppressive effect of DEX were
seen even though the hypothalamus, along with the
pituitary, was inhibited. In sum, the dissimilarities in
the regulatory responses of rats treated with CORT versus
DEX still remained whether one or both of the primary
feedback sites along the adrenocortical axis are
inhibited. This suggests the differential affinity of
these steroids at the hypothalamus and pituitary is not
critical to their effects on body weight and food intake.
Another aspect of the action of CORT and of DEX is
their mineralocorticoid properties. CORT has some salt-
retaining effects, while DEX doesn't. However, in the
present study when rats had access to 2% saline solution,
no statistical differences in saline intake emerged
between groups and the trends that occurred were in a
direction counter to that predicted. However, Simpson et.
al. (178) also found an increase in saline intake with
successive injections of CORT and no change upon exposure
to DEX. This suggests that the difference in the
mineralocorticoid properties, at least with respect to
Na+, possessed by these two hormones did not play a
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significant role in the divergent ingestive patterns
produced
.
Another difference between these hormones is
important to note. In both sham-operated and KC rats,
chronic exposure to DEX, but not CORT, reduced linear
growth. Attenuated growth has previously been revealed
after long-term treatment with some glucocorticoids (52,
63, 140). Conversely, elongated body length has been noted
following PVN KCs (47, 48, 49).
One of a number of properties of DEX may have yielded
this effect on growth. Negative feedback inhibition by
DEX on pituitary ACTH (156, 157) and B-endorphin (58)
release has been demonstrated. While the pituitary
content of growth hormone is normal in DEX-treated rats
(140), DEX's inhibitory action may include depression of
pituitary growth hormone secretion. However, in seeming
paradox, Wehrenberg and colleagues (203) have shown that
chronic DEX treatments enhance the pituitary growth
hormone response to intravenously-applied growth hormone-
releasing factor (hp GRF-44) in vivo. From this, along
with other evidence, these investigators suggest that one
way DEX attenuates growth is by depressing the CNS
pathways that regulate normal growth hormone secretion.
However, the exogenous addition of GH did not reverse the
diminished body lengths produced by long-term exposure to
the adrenocorticoid, methylprednisolone (53). The
inhibitory effects of DEX on somatic growth may relate to
this steroid 's actions in the periphery. In augmenting
the production of glucose, glucocorticoids promote
mobilization of tissue protein, transport of derived amino
acids to the liver, and decrease utilization of amino
acids in muscle and fat (19, 60, 100, 194), DEX, more
than CORT, may encourage the use of proteins for glucose
production at the expense of linear growth.
The present results reveal that marked differences in
the response to CORT versus DEX occur, and that the
results obtained with one glucocorticoid cannot be
extended to another.
The next experiment examined whether the
dissimilarities between these hormones may be attributed
specifically to the action of DEX at the adrenal medulla.
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CHAPTER IV
EXPERIMENT III
In Experiment 3, the nature of DEX's effects on rats
with PVN KCs was explored further. The steroid hormone DEX
acts at several sites. After hypophysectomy (4, 39, 83,
197, 207, 208) or adrenal denervation (4, 143, 197) DEX
restores the activity of the enzymes (TH, DA-B-OH, PNMT)
that synthesize CAs in the adrenal medulla. This includes
the reinstatement of medullary CA responses to stress (4,
39, 83), and to peripheral injections of 6-hydroxy-
dopamine (197). In comparison to exogenously administered
CORT, DEX has a greater capacity to induce CA biosynethic
enzyme activity in the adrenal medulla (208). DEX is an
especially potent enhancer of medullary PNMT activity
(143, 207, 208). The action of DEX at the adrenal medulla
may account for the ability of this steroid to reduce the
body weight gain of PVN KC rats. To determine whether DEX
acts via the adrenal medulla to produce the responses
observed in Experiments 1 and 2, DEX was administered to
rats that underwent PVN KC or sham brain surgery after the
removal of adrenal medullae (experimental phase 3a).
The primary site of the negative feedback action of
DEX is the anterior pituitary. DEX exhibits a higher
binding affinity to anterior pituitary cells (34, 148),
and a greater degree of inhibition of ACTH release at the
pituitary level (156, 157), than does the natural
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glucocorticoid CORT (147, 156, 157) To determine whether
the responses produced by DEX are due to its inhibition of
pituitary ACTH, KC and sham-operated rats with intact or
demedullated adrenals were given ACTH treatments in
combination with DEX (experimental phase 3b).
General Methods
Forty adult 250 gram female albino Charles Rivers CD
rats were singly housed in stainless steel cages under a
12:12hr light :dark illumination cycle. Purina Laboratory
Chow pellets (#5001) were available ad libitum until the
time of brain surgery. Thereafter the rats were
maintained on Purina Mouse Chow pellets (#5015). Free
access to water was provided throughout the experiment.
Bilateral adrenal demedullation surgery was performed
on half the rats. Under ether anesthesia the adrenal
glands were located through bilateral incisions in the
dorsal side of the body wall. Each gland was exposed by
gently teasing away surrounding fat tissue with care taken
to keep the blood supply to the gland intact. On each
side, the adrenal was punctured and slit at the posterior
pole of the gland with a #12 scalpel. The adrenal medullae
was squeezed out and removed. The remaining cortical
tissue and surrounding fat was then be returned to the
body cavity.
All other subjects received control surgery which
consisted of identical procedures excluding incisions of
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the adrenal glands and extrusion of the medullae.
For 4 postoperative days rats had continuous access
to a 0.85% saline solution in addition to water. This
allowed rats to compensate for temporary deficits in
minerocorticoid secretion that may exist after surgical
insult to the adrenal cortex. Animals were monitored for
persistent excessive intake of the saline solution and
poor health upon removal of the saline. No rats exhibited
these behaviors suggesting none suffered from inadequate
adrenocortical functions as a result of adrenal surgery.
Seven to twelve days after adrenal demedullation or
sham demedullation half the rats from each of these groups
received bilateral parasagittal retracting wire knife cuts
alongside the PVN. The other half of each group underwent
sham brain operations. Hypothalamic knife cut surgery was
executed as described in Experiments 1 and 2.
DEX treatment began one day prior to brain surgery.
Rats treated with DEX were given a 0.1 mg/kg/day dose via
the drinking water. It was administered as in Experiment
2.
To summarize, a 2 x 2 x 2 design yielded eight
experimental groups as follows: knife cut (KC) or sham
knife cut; and demedullation (DEM) or sham demedullation
(ie. adrenal intact); hormone (DEX) or no hormone (CON),
(n=5)
.
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Experimental Phases
In the Initial treatment phase (3a) DEX or no hormone
(CON) was administered for 8 days following knife cut or
sham KC surgery.
In the next treatment phase (3b) ACTH injections were
combined with the DEX or the CON condition. From Day 9 to
Day 13 after brain surgery, all rats were Injected just
after lights 'on' and just prior to lights 'off with 8 U
of the ACTH gel Cortigel-40 (Savage Laboratories,
Melville, New York). Following ACTH treatment, rats were
continued on DEX or CON alone for about 1 week (Phase 3c).
Thereafter, rats were withdrawn gradually from DEX.
Body weight, water intake, and food intake accounting
for spillage were measured throughout each phase of this
experiment.
Urinalysis for glucose was performed periodically. In
this experiment, a urine sample was collected by placing a
clean piece of cellophane plastic wrap under the home cage
and waiting for a testable sample. While samples were
collected, water bottles were absent from the cages. Food
was removed from rats that tended to eat during the day.
Urine glucose content was measured using Diastix Reagent
Strips
.
Blood Glucose Samples
Blood samples for glucose determination was taken at
the end of the initial DEX exposure phase (Day 8) and at
the end of the ACTH treatment phase (Day 14). The protocol
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that was used for collection and storage of samples was
described in Experiment 2.
Surgical Verification
At the conclusion of the experiment rats were
assessed for completeness of adrenal demedullation under
Nembutal anesthesia. Using a dorsal approach, the adrenals
were located, isolated, and then examined under a 20X
Zeiss operating microscope for evidence of medullary
tissue. A sham brain-operated and a KC rat were considered
to have incomplete demedullations and were eliminated from
the experiment.
Rats with PVN KCs were perfused, and brains were
removed and stored in a formalin fixation solution.
Criterion utilized to verify the accuracy of PVN KC
surgery were as indicated in Experiment 1 and resulted in
two rats being dismissed as subjects.
Because the accuracy of the adrenal demedullation and
the PVN KC surgery of a KC/DEM rat was each debatable,
this subject was also removed from the study. Finally, a
KC/DEX rat died during the experiment removing it from
consideration. The loss of several subjects in this study
unfortunately left the experimental treatment groups small
in size. This should be kept in mind while assessing the
data and its discussion.
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Results
Body Weight
Phase 3a> A 2 x 2 x 2 ANOVA of the cumulative weight
change over the Initial experimental phase revealed a
significant main effect for the KC surgery (F( 1 , 26 ) =306 . 2
,
p<.05) and the hormone (F( 1 , 26 ) =136 . 3 , p<.05) conditions
but not for the adrenal surgery. There were also
significant two-way Interaction effects for brain surgery
by hormone (F( 1 , 26 ) =12 . 3 , p<.05), and hormone by adrenal
surgery (F( 1 , 26 ) =10 . 8 , p<.05) In addition to a significant
three-way Interaction between brain surgery by hormone by
adrenal factors (F( 1 , 26 ) =11 . 0 , p<.05) (Figure 10).
As In the preceding experiment, chronic DEX
treatments suppressed body weight. In sham brain-operated
rats, prior adrenal demedullatlon did not alter the
suppressive effects of DEX on body weight. Adrenal
demedullatlon alone failed to Influence the body weight
gain of vehicle-treated sham brain-operated rats.
DEX also attenuated the weight gain typically seen
subsequent to PVN KC surgery (KCs, Hormone: F( 1 , 11 ) =51 . 9
,
P<.05). This attenuation effect was not prevented by
adrenal demedullatlon. However, there was an Interaction
between adrenal demedullatlon and DEX over time (KCs,
Hormone x Adrenal x Days: F( 7, 77) =5. 01, p<.05). The weight
gain of DEX-treated adrenal demedullated KC rats versus
DEX-treated adrenal Intact KC rats diverged after Day 6 at
which time the the body weight curve of the demedullated
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Figure 10. Mean body weight change of
sham-operated and PVN KC rats with intact or
demedullated (DEM) adrenal glands and treated
with no hormone (CON) or 0.1 mg/kg DEX in each
phase (A - C) with the addition of ACTH
(8 U, 2 X day) during Phase B.
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Days From Surgery
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rats flattened while that of adrenal intact rats was
further reduced by DEX (KCs, Hormone x Adrenal Surgery:
F(l,ll)=11.4, p<.05; Duncan, p<.05).
Adrenal demedullation alone also slowed the excessive
weight gain of KC rats. Demedullated KC vehicle-treated
rats gained less weight over Phase 3a than adrenal intact
KC vehicle-treated rats (p<.05). Again the effects of
demedullation on body weight was delayed, more substantial
differences emerging between Days 6-9.
Phase 3b. An overall ANOVA for the mean body weight
change upon exposure to ACTH in Phase 3b yielded
significant main effects for brain surgery (F( 1,26) =27. 4,
p<.05) and hormone (F( 1,26) =42. 4, p<.05), and significant
effects for brain surgery by hormone (F( 1 , 26 ) =18 . 7 , p<.05)
and brain surgery by hormone by adrenal surgery
(F(l,26)=6.5, p<.05) (Figure 10).
The weight gains of vehicle-treated sham brain-
operated groups were not affected by ACTH. ACTH treatments
also did not reverse the suppressed body weight of DEX-
treated sham-operated rats. However, further weight loss
in DEX-treated sham brain-operated rats with intact
adrenals was curtailed by ACTH. These rats lost
significantly less weight during the ACTH treatment period
than previously (Phase 3a, Day 4-8: -3.55 +0.31 g/day
versus Phase 3b: 0.02 + 0.61 g/day; correlated t(4)=5.116,
Bonforroni adjusted familywise error rate, p<.0167) such
that their weight change was not different from that of
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either sham brain-operated group not exposed to DEX.
Similar results were not obtained in DEX-treated brain
intact rats with demedullated adrenals in response to
ACTH.
Attenuated body weight gains were still seen in both
KC groups treated with DEX when ACTH was presented in
Phase 3b (KCs, Hormone: F( 1,11) =26. 8, p<.05). However,
while a further decline in weight occurred in the adrenal
intact KC group under the combined DEX and ACTH treatment,
no change in weight was seen in the demedullated KC group.
This found DEX-treated KC rats with demedullated adrenals
outweighting DEX-treated KC rats with intact adrenals in
Phase 3b (p< .05)
•
The introduction of ACTH also did not significantly
alter the rate of weight gain of KC groups not treated
with DEX (Phase 3a vs Phase 3b vs Phase 3c, n. s.)-
However, it appeared to enhance the weight gain of the
adrenal enucleated KC rats as this group did not differ
from adrenal intact KC rats in absolute weight gain in
Phase 3b as they did in Phase 3a.
Phase 3c. A 2 x 2 x 2 ANOVA of the mean body weight
change over Phase 3 revealed significant effects for the
hormone (F(l,26)=14.7,p< .05) and brain surgery factors
(F(l,26)=14.8, p<.05), and for the brain surgery by
hormone interaction (F( 1 , 26 ) =5 . 6 , p<.05) (Figure 10).
Only having a brief five day post-ACTH phase makes
the outcome of this phase difficult to interpret. All
108
groups exhibited similar rates of weight change in this
phase as in the previous phase when ACTH was presented.
This suggests that the weight change in Phase 3b may
relate to time from surgery and not to ACTH effects. But
residual ACTH effects may have been present in Phase 3c
and instead may have been reflected in the response of
some groups during this phase.
The diminished level of weight gain obtained by
adrenal intact KC rats exposed to DEX plus ACTH in Phase
3b continued into Phase 3c even though ACTH was withdrawn.
In contrast to DEX-treated adrenal intact KC rats, the
weight gained by DEX-treated demedullated KC rats was
comparable to vehicle-treated KC groups in Phase 3c.
Food Intake
Phase 3a. A 2 x 2 x 2 ANOVA of the quantity of food
consumed during Phase 3a revealed a significant main
effect for KC surgery (F( 1,26) =380. 6, p<.05) and a
significant brain surgery by hormone interaction
(F(l,26)=6.7, p<.05) (Figure 11).
In brain intact rats, exposure to DEX attenuated food
intake of both adrenal intact and demedullated groups
(SHs, Hormone: F( 1 , 15 ) =87 . 4 , p< .05) . However, regardless
of their hormone treatment or adrenal condition, all KC
groups exhibited a similar elevation in food intake
subsequent to brain surgery. This contrasted the food
intake response seen in DEX-treated KC rats in earlier
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experiments
.
Phase 3b. Significant brain surgery (F( 1 , 27 ) =246 • 7 ,
p<.05) and DEX treatment (P( 1 , 27 )=12 . 5 , p<.05) main
effects and a significant 3-way brain surgery x hormone x
adrenal surgery interaction effect (F(l,27)= 7.5, p<.05)
emerged from a 2 x 2 x 2 ANOVA of the mean amount of food
consumed over Phase 3b (Figure 11).
ACTH countered the suppression of feeding by DEX in
adrenal intact sham brain-operated rats (SH/CON vs SH/DEX:
Phase 3a, p<.05; Phase 3b, n.s.). Whereas, demedullation
prevented this effect of ACTH on food intake (SH/DEM vs
SH/DEM/DEX, Phase 3a and 3b, p<.05). (SHs, Hormone x
Adrenal Surgery: F( 1 , 15 ) =19 . 4 , p<.05).
An elevation in food intake was still exhibited by
each KC treatment group under in Phase 3b. The intake of
adrenal intact KC rats not exposed to DEX was enhanced by
ACTH (Duncan, p<.05 versus other KC groups in Phase 3b;
Bonforroni correlated t, adjusted EF, p<.0167 versus Phase
3a) while the consummatory response of the other KC groups
was not significantly altered.
Phase 3c. With the removal of ACTH, the amount of
food consumed by sham-operated rats was again as seen in
Phase 3a. The potentiated food intake of adrenal intact KC
controls subsided in Phase 3c confirming its mediation by
ACTH (Figure 11)
.
Water Intake
Neither exposure to DEX nor prior adrenal
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demedullation altered the water intake of sham-operated
rats. The addition of ACTH (Phase 3b) also had no impact
(Table 14 )
.
As typically found, KC rats drank significantly more
water per day than sham-operated rats (Phase 3a, Brain
Surgery: F( 1 , 26 ) =33 . 62 , p<.05). The water intake of KC
rats proved to be sensitive to DEX and adrenal surgery
(Brain Surgery x Hormone: F( 1 , 26 ) =4 . 52 , p<.05; Brain
Surgery x Adrenal Surgery: F( 1 , 26 ) =10 . 4 , p<.05). Exposure
to DEX radically elevated the already high water intake of
KC rats with intact adrenals without influencing the
quantity of water ingested by DEX-treated KC rats with
demedullated adrenals (p<.05).
ACTH (Phase 3b) failed to reverse the polydipsia of
any KC groups. Indeed, introduction of ACTH tended to
augment the already elevated water intake of the adrenal
intact KC rats, but not of the demedullated KC rats.
However, this change did not reached statistical
significance.
Blood Glucose
In sham brain-operated rats, DEX and/or ACTH
slightly enhanced circulating glucose levels (Table 15).
Prior demedullation tended to block this enhancement.
PVN KC surgery alone caused a small increase in serum
glucose which was slightly but not significantly
diminished by demedullation. The main effect was that DEX
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produced an elevation five times normal (!!?) in the blood
glucose of KC rats with intact adrenals. ACTH increased
blood glucose even more. In contrast, this dramatic
hyperglycemia was entirely blocked by the prior
demedullation of KC rats.
Urinalysis
No urine glucose was found any sham brain-operated
rats at any point during Experiment 3.
In concert with the water intake and blood glucose
values, glycosuria was observed in DEX-treated KC rats
with intact adrenal glands. By Day 2 post-KC surgery,
urine glucose in amounts ranging from +1/4 (250 mg/dl) to
+1 (1000 mg/dl), was detected in 3/4 of the rats in this
group. By Day 7, urine glucose concentrations of +1 (1000
mg/dl) were seen in all rats in the adrenal intact KC/DEX
group. At the end of experiment 3b (Day 13-14), urine
glucose values had elevated to +2 (2000 mg/dl) in 3/4 of
these rats suggesting that their glycosuria was
potentiated by ACTH. Glycosuria was never detected in any
of the other three KC groups.
Discussion
This experiment attempted to eludicate the underlying
nature of the suppression of food intake and body weight
by DEX seen in the preceding experiments.
The posited role of the adrenal medulla in mediating
the suppressive effects of 0.1 mg/kg DEX was examined.
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Support for this notion was mixed. Experiment 3 revealed
that the adrenal medulla participates in DEX's effects on
glucose homeostasis. Yet, the role of this site in DEX's
attenuation of body weight was not obvious.
In sham brain-operated rats removal of the adrenal
medullae did not prevent the suppression of body weight or
food intake by DEX. This suggests that DEX does not act
via the adrenal medulla to produce its effects in these
rats. In contrast, in KC rats removal of the adrenal
medullae did partially protect the rats from the
suppression of weight gain by DEX. Severe hyperglycemia,
polydipsia, and glycosuria were exhibited by DEX-treated
KC rats with intact adrenals in this study. Thus, the
lower cumulative weight gain of these adrenal intact KC
rats likely reflects the urinary caloric loss. The altered
glucose homeostasis that produced this condition indicates
that adrenal medullary CAs potentiate the action of DEX as
adrenal demedullation prevented the glycosuria. The
involvement of other sites in DEX's suppressive effects is
also suggested. Demedullated KC rats treated with DEX
gained less cumulative weight than KC groups never exposed
to DEX, although by experimental phase 3c DEX-treated
demedullated KC rats were gaining weight at a rate
comparable to the latter KC groups.
DEX induces PMNT in the adrenal medulla and more so
in rats with compromised neural or humoral inputs to this
tissue (eg. 68, 203, 204). It is plausible that
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adrenomedullary E causes the elevated glucose levels in
DEX-treated adrenal intact rats, as E produces
hyperglycemia by a range of metabolic processes including
gluconeogenesis and glycogenolysis and the mobilization of
fuels (eg., lipolysis) to synthesize glucose (19, 60,
195). Also glycosuria has been noted to accompany the
oversecretion of CAs (eg. pheochromocytoma
, CA-secreting
tumor) (195). ACTH's potentiation of glucose levels here
also appears to be adrenal medullary CAs.
Additional insight into the nature of the
relationship between adrenal medullary function and PVN KC
obesity is provided by other findings from Experiment 3.
Clearly, the obesity seen subsequent to disruption of the
PVN cannot be attributed to a loss of adrenal medullary
functions, because complete removal of the medullae did
not potentiate the obesity of KC rats, nor did it cause
obesity in brain intact rats. On the contrary, adrenal
demedullated KC rats had lower cumulative weight gains
than did adrenal intact KC rats.
Perhaps disruption of paraventricular connections
alters the functional status of the adrenal medulla in
some qualitative fashion so as to contributes to the
obesity that results. One qualitative aspect of adrenal
medullary function that is posited to be compromised by .
PVN disconnection is the activity of the medullary CA
biosynthetic pathway. KCs alongside the PVN disrupt the
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humoral and neural factors that modulate the enzymes
governing the proportions of E and NE that are produced
(see Introduction). The adrenal medullary CA response
most compatible with the development of obesity is a
reduction in the levels of E versus NE as this would
encourage a tendency toward deposition of fuels over
mobilization and utilization. PVN KC rats are reported to
have lowered E levels along with reduced E/NE ratios
(50). More work is needed to sufficiently determine their
role in KC obesity.
Alternative explanations can be put forth for the
reduced weight gain seen in demedullated KC rats.
Demedullation may actually serve to increase sympathetic
activity. For instance, a denervation supersensitivity
response can follow the removal of sympathoadrenomedullary
tissue and serve to increase the activity of the remaining
SNS (60). Also distruction of one aspect of the SNS can be
accompanied by reflex compensatory increases in CA
synthesis in the complementary intact branch (es) of the
SNS (60, 132, 133, 134, 127, 198, 196). Possibly the
lower feed efficiency of demedullated KC rats reflects
this enhanced sympathetic activity.
It is possible that the lower weight gain of
demedullated KC rats is due to inaccuracies in PVN KC
surgery or to insufficiencies in adrenocortical functions.
Both the KC and demedullation surgeries were verified. The
food intake of the demedullated KC rats was also
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comparable to that of adrenal intact KC controls. This
suggests that all of the KCs were equivalently placed. The
adrenal demedullation surgery may have disturbed the
function of the adrenal cortex to produce the attenuated
weight gain of the demedullated KC rats. However,
demedullation surgery did not eliminate the initial post-
KC surgery weight gain or cause excessive postoperative
consumption of a saline solution (data not shown), nor did
it impair the weight gains of sham brain-operated rats.
But ACTH did appear to potentiate the weight gain of the
demedullated KC rats.
From the present work it appears that DEX's action at
the adrenal medulla does not comprehensively explain its
suppression of consummatory responses. DEX's negative
feedback action at higher centers was therefore also
examined. Supplementing DEX with ACTH in Phase 3b did not
reverse the attenuation of body weight produced by DEX.
Thus, it does not appear that DEX acts on food intake and
body weight by inhibiting ACTH release.
Some of the responses that accompanied the
administration of ACTH in experimental phase 3b seem to
point instead to the adrenal medulla as capable of
influencing ingestive behavior. For instance, an elevation
in food intake accompanied the administration of ACTH in
KC rats with intact adrenals but not in demedullated KC
rats. Also, DEX-treated sham brain-operated rats with
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intact adrenals normalized their weight and food intake
when ACTH was administered, while DEX-treated demedullated
rats did not.
The increases in circulating endogenous CORT
stimulated by ACTH should be identical in rats with intact
versus demedullated adrenals . However, exogenously-applied
ACTH also increases the concentration of endogenous CORT
perfusing the intra-portal adrenal system to the adrenal
medulla. Adrenomedullary CA synthesis indirectly induced
by ACTH would seem to account for the differential
responses seen between rats possessing and those not
possessing medullary tissue.
The exact physiological significance of the
consummatory responses produced by ACTH is not clear.
However, they imply that ACTH has the potential to alter
the balance of adrenomedullary E and NE available to
influence consummatory behavior.
The action of DEX at several sites may contribute to
the responses seen. For instance, glucocorticoids maintain
the level of adrenergic activity in the sympathetic
nervous system particularly in the superior cervical
ganglion (14, 22, 191, 195, 200). The effects of KCs
alongside the PVN on the sympathetic nervous system are
not exclusive to the adrenal medulla. Transection of the
PVN is thought to alter the tonus of the entire
sympathetic nervous system. Although Indicated as an age-
dependent effect by some (13, 74), many studies have
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demonstrated that the administration of DEX can enhance CA
levels and CA synthesizing enzymes including E and PNMT in
sympathetic ganglia and extraadrenal chromaffin cells
(12, 142, 191). This entertains the possibility that the
actions of DEX encompass enhancement of sympathetic CA
activity in general.
The influence of DEX at the liver, pancreas, adipose
tissue, or muscle may also be involved. Glucocorticoids
affect the metabolic processes or secretory states at all
of these sites (19, 60, 100, 195). In addition, the
effects of CA^s on these functions are potentiated by
glucocorticoids (38, 100, 195) . Hence, the suppressive
effects of DEX in this study may relate to actions at
several sites. For this to be the case DEX must exert
itself in a fashion that differs qualitatively from CORT
because the administration of CORT in a wide range of
dosages does not produce the suppressive effects of DEX.
Some have noted that CORT acts in the manner that differs
from synthetic glucocorticoids, particularly prednisolone-
based corticoids such as DEX (100, 140, 178).
Finally, the results from this experiment contrast
findings from Experiment 2. In testing drug regimens in
the first two experiments, it was demonstrated in
Experiment 2 that a 0.1 mg/kg dose of DEX, when adjusted
daily in a alcohol vehicle via drinking water, stabilized
the weight gain of KC rats with intact adrenals and
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reduced their food intake. This effect was produced in
Experiment 2 with minimal glycosuria and without altering
water intake. Thus, 0.1 mg/kg DEX via this administration
procedure was considered suitable to use in the succeeding
studies
.
However, when this DEX regimen was extended to
Experiment 3 and presented from the time of brain surgery,
a significant glycosuric condition consistently appeared
in adrenal intact KC rats treated with DEX. It was
accompanied by a greatly elevated water intake, a
compensatory response to renal fluid losses. Also
contrasting the results of Experiment 2, no reduction in
food intake was seen in DEX-treated KC rats with intact
adrenals in Experiment 3. At least a component of the
overeating seen under these latter circumstances may be in
compensation for the glycosuria.
There is an intricate balance between the suppression
of body weight and food intake by DEX, and the occurrence
of glycosuria. DEX can influence body weight and food
intake without glycosuria or polydipsia being a factor. On
the other hand, the effects of DEX on KC animals can be
obscured by secondary effects created by severe
hyperglycemia and the excretion of calories. Thus, the use
of the 0.1 mg/kg dose of DEX in Experiment 3 did not serve
after all to capitalize on this experimental paradigm and
maximize the production of coherent results. In other
words, it produced confounded results. This dose given
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every other day or a lower dose such as 0.05-0.075 mg/kg
might have more clearly delineated the relationship
between DEX's suppressive effects and its action at the
medulla.
The time point of exposure following KC surgery may
have been a factor. In Experiment 2 where glycosuria did
not contribute significantly to responses produced, rats
were not treated with 0.1 mg/kg DEX immediately after KC
surgery as in Experiment 3 , but were introduced to it
approximately a week later following exposure first to a
0.05 mg/kg dose of DEX. Experiencing a gradual
introduction to the higher 0.1 mg/kg DEX dose could play a
role in the differential responses.
The age of the rats used in these studies also
differed. The rats used in Experiment 2 were 2-2 1/2
months old at the beginning of the study, while the rats
in Experiment 3 were 3 1/2 - 4 months old. Age differences
in characteristics such as growth, metabolic rate, and
thermogenic capacity may be a source of the incongruous
responses produced by DEX in Experiment 2 versus 3
.
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CHAPTER V
GENERAL DISCUSSION
KCs alongside the PVN sever CRF-positive
paraventricular to infundibular neural projections, thus
reducing the responsiveness of the pituitary-
adrenocortical system. The present work indicates that
deficits in the availability of circulating CORT do not
produce the overeating and obesity that follow PVN KCs.
CORT supplements did not block the hyperphagia or obesity,
even when CORT was provided continuously (Experiment 1)
or in resemblance to a normal diurnal cycle (Experiment
2). A deficit in ACTH also does not appear to be
responsible for hypothalamic obesity, as KC hyperphagia
and obesity were not blocked by ACTH and its enhancement
of endogenous CORT (Experiment 3).
Deficits in CA biosynthesis within the adrenal
medulla were also hypothesized as possibly contributing to
the obesity seen after PVN KCs. DEX was employed to test
this hypothesis because of its documented ability to
restore CA deficits. KC rats treated with DEX did have
attenuated feeding and weight gains. This response was
seen in the absence of confounds associated with steroid
diabetes (Experiment 2).
However, the reasoning that DEX produces this
suppression of regulatory responses via the adrenal
medulla was not fully supported. Suppressions in body
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weight and sometimes food intake were still seen in
adrenal demedullated animals treated with DEX (Experiment
3).
Yet, the effects of DEX are potentiated in the
presence of the adrenal medulla as indicated by the
dramatically raise peripheral glucose levels in KC rats.
Incidence of a DEX-induced diabetic condition, consisting
of severe hyperglycemia, glycosuria, polydipsia, and
weight loss, were seen only in KC rats with intact
adrenals and not in those with demedullated adrenals. Even
when glycosuria was not present, significant elevations in
blood glucose levels were found in adrenal intact KC rats
administered DEX. Slight increases in serum glucose were
also present in DEX-treated adrenal intact, but not
demedullated, brain intact rats.
The extent to which the hyperglycemia mediated by the
medulla relates to DEX's attenuation of appetitive
responses is not determined from the present work. How
this glucose response relates to the physiological changes
underlying KC-induced obesity is also not clear. The
sympathoadrenomedullary response to insulin- induced
hypoglycemia is under central control (182). Also,
activation of the extrahypophysial CRF system associated
with the caudal hindbrain projection system of the PVN
does result in increases in blood glucose (21, 23, 24, 25)
presumably largely via peripheral CAs (21, 24).
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Adrenomedullary E appears to be responsible for the
altered carbohydrate metabolism produced by DEX in adrenal
intact KG rats. E, acting primarily via -adrenergic
receptors, increases blood glucose and hepatic
glycogenolysis (84). The dissociation of these E-mediated
hyperglycemic effects from E ' s anorectic effects has been
demonstrated (84). Similarly, the changes in glucose
balance induced by DEX were shown to be exaggerated by the
presence of adrenal medullary CAs, while this was not
established for the changes DEX produced in consummatory
responses
.
However, the adrenal medulla was not found to be the
only nor the major site at which DEX acts to suppress body
weight. Hence, we cannot adhere to the premise that DEX
reverses deficits in adrenomedullary CA activity produced
by KCs to reduce the resultant obesity. In turn, we
cannot draw definitive conclusions about the relationship
between the obesity seen subsequent to KCs alongside the
PVN and altered adrenomedullary CA activity. Other
experimental approaches that utilize direct measures of
adrenal medullary activity and function would more
adequately examine this relationship.
For instance, it first should be established that
this type of PVN KC procedure does indeed alter the
balance of E to NE synthesized in the adrenal medulla.
Direct measures of adrenal NE and E content, turnover, and
release, along with the activity of CA biosynthetic
enyzmes in adrenal intact KC rats should be performed. If
diminished CA production and secretion is found in these
rats, then its role in the ingestion and weight gain seen
after KC surgery should be explored. One approach might
comprise the replacement of more than just one adrenal
secretion following adrenalectomy in KC rats. In varying
amounts and ratios, CORT, NE, E, (and mineralocoid) could
be administered in an attempt to titrate the relative
involvement of CAs in the obesity seen after KCs. To
examine how alterations in the neural and hormonal inputs
regulating CA production in medullary tissue relates to
PVN obesity, another agent that activates (or inhibits) NE
and/or E production, and that has less ubitiquitous
effects on body tissues than does DEX, could be employed.
Another significant finding emerging from the present
work is that DEX and CORT differ in their effects on body
weight and food intake. As mentioned previously, these
regulatory responses were attenuated by DEX, but were
affected negligibly by CORT. Others have reported similar
responses after administering DEX (7, 69, 104, 140, 178)
or CORT (140, 178) to normal rats. One of several
properties in which disparities between DEX and CORT exist
may be responsible for the incongruous effects they have
on consummatory responses. Agruments were made herewithin
against the role of disparities in their potency,
mineralocorticoid effects, and site(s) of negative
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feedback. Neither did differences in their action at the
adrenal medulla or their promotion of blood glucose fully
account for it (see discussion sections. Experiments 1, 2,
and 3). Other evidence suggests that alterations in the
activity level of rats also do not underlie the deviations
in food intake and body weight produced by DEX (7, 69). It
still remains unclear what the basis of the contrasting
consummatory responses produced by DEX and CORT is. Some
other possible explanations exist:
Reduced growth and weight gain were not produced by
chronic exposure to CORT in this work nor in that of
others (140, 178). In contrast, some pieces of evidence
suggest that the suppressive effects of DEX may relate to
its interaction with the growth hormone (GH) system, but
the exact nature of their interrelationship is difficult
to elucidate. Chronic exposure to DEX reduces food intake,
body weight, and linear growth, and also makes rats more
responsive to the exogenous application of GHRF (203).
Somatomedins, a family of peptides released from the liver
under GH control, decrease food intake and body weight
when centrally applied (194). This peptide also
suppresses GH secretory bursts via its feedback
stimulation of the inhibitory hypothalamic hormone,
somatostatin (194). In turn, KCs alongside the PVN
increase food intake, body weight, and linear growth (47,
48, 49). Somatostatin has been identified in the PVN (158,
163, 187). These data suggest that an interesting
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interplay may exist between the action of DEX (at the
brain or possibly the anterior pituitary), the regulation
of the GH system, and consummatory responses. More work is
needed to clarify and support this possibility.
The incongruous effects of DEX and CORT may be due to
the differential action of these steroids at one or
several peripheral sites such as the liver, pancreas,
adipose tissue, or muscle. CORT and DEX may differ in
their effects on metabolic processes that are mediated by
glucocortiocoid action at these sites and that contribute
to the homeostatic responses and the energy balance of an
animal. An example is the discrepancy that exists in the
glucose-induced insulin response seen in the presence of
CORT and DEX (100) in an in vitro preparation. Insulin
secretion is inhibited when CORT, but not DEX, is added.
An another example can be derived from the differences in
growth seen upon exposure to CORT versus DEX. This
suggests that these glucocorticoids may differ in their
promotion of the use of amino acids as a fuel and/or in
their activation of gluconeogenesis
.
CORT and DEX may also influence the nervous system in
different ways leading to the elicitation of different
regulatory responses. Some evidence does indicate that
differences exist in modulatory effects of these steroids
on CAc activity in the brain (127, 206) and superior
cervical ganglion (191).
129
The differences in the effects of CORT versus DEX at
various sites may entail differences in their
intracellular binding properties. Dissimilarities in
characteristics such as receptor type and location, and
binding specificity and affinity have been revealed for
DEX and CORT in some instances. Some sites at which
dissimilar binding profiles have at times been noted
between CORT and DEX include the superior cervical
ganglion (14, 191, 200), liver (1), and brain (34, 147,
148, 180), anterior pituitary (34, 148), and in the blood
(as stated in 1, 200).
Concluding, the present work indicates that marked
differences exist between the effects of CORT and DEX. It
revealed that the properties that characterize one
glucocorticoid cannot necessarily be extended to another.
Thus DEX (and probably other prenisolone-based steroids)
should not be considered a glucocorticoid in the same
sense that CORT is. These findings also bring into
question whether all properties that are traditionally
attributed to glucocorticoids as a class actually do
represent the actions and effects of each compound
considered a glucocorticoid. The recognition of this
difference is particularly relevant with regard to the
medical treatment of obese or diabetic-prone individuals
with DEX or other prednisolone-based glucocorticoids.
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